Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 1 
CONFIDENTIAL   
Clinical Study Protocol : ORA -D-012 
Study Title:  A Phase 2a , Randomized, Double -Blind, Double -Dummy, Placebo -
Controlled, [ADDRESS_427170] Crossover S tudy to Compare Safety, Efficacy 
and Pharmacodynamics of Single and Multiple Doses of ORMD -
0801 or Placebo in Adult Subjects  with Type 2 Diabetes Mellitus  
Protocol Number:  ORA -D-012 
Study Phase:  Phase 2a 
Principal 
Investigator : [INVESTIGATOR_65758] M. Neutel, M .D. 
Orange County Research Center  (OCRC)  
[ADDRESS_427171]. , Suite B , Tustin , CA [ZIP_CODE]  
Sponsor:  Oramed Ltd. 
Hi-Tech Park 2/5 Givat Ram  
[PO_BOX]  
Jerusalem, [ZIP_CODE], Israel  
Name [CONTACT_344288]:  Miriam Kidron, PhD  
Chief Scientific Officer and Director  
Oramed Ltd . 
Protocol Version:  1 
Date of Version:  August 23, 2016  
CONFIDENTIALITY STATEMENT :  THIS DOCUMENT IS THE PROPERTY OF ORAMED LTD. AND 
MAY NOT —IN FULL OR IN PART —BE PASSED ON , REPRODUCED , PUBLISHED , OR DISTRIBUTED 
TO ANY PERSON , OR SUBMITTED TO ANY  REGULATORY AUTHORITY , WITHOUT THE EXPRESS  
WRITTEN PERMISSION O F ORAMED LTD. OR THEIR OFFICIA L REPRESENTATIVES . 

Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 2 
CONFIDENTIAL  SPONSOR PROTOCOL APPROVAL SIGNATURE [CONTACT_248480]. ORA -D-012 for issuance : 
 
Miriam Kidron, PhD  
Chief Scientific Officer and Director  
Oramed Ltd.   
 
 Signature   [CONTACT_344289].   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427172] read the attached protocol and agree that it contains all the necessary details for 
performing the study.  
I will provide copi[INVESTIGATOR_344241]’s Brochure (IB), which was 
furnished to me by [CONTACT_1034], to all members of the study team responsible to me who 
participate in the study.  I will discuss this material with them to assure that  they are fully 
informed regarding the study treatment , including the potential risks and side effects, and the 
conduct of the study.  
Once the protocol has been approved by [CONTACT_4707] (IRB), I will not modify 
this protocol without obtaining the prior approval of the Sponsor and of the IRB.  I will submit 
the protocol modifications and/or any informed consent form (ICF) modifications to the Sponsor 
and the IRB, and approval will be obtained before any modifications are implemented.  
I understand the protocol and will work according to it, the principles of Good Clinical Practice 
[GCP; current International Council for  Harmonisation  (ICH) guidelines], and the Declaration of 
Helsinki (1964) including all amendments up to and including th e October 2013 revision . 
 
Joel M. Neutel, M.D.  
Principal Investigator  
[INVESTIGATOR_344242].   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427173] Crossover S tudy to Compare Safety, Efficacy and 
Pharmacodynamics of Single and Multiple Doses of ORMD -0801 or 
Placebo in Adult Subjects  with Type 2 Diabetes Mellitus  
Indication  Type 2 Diabetes Mellitus (T2DM)  
Clinical Phase  Phase 2a 
Study Treatment 
Dose  
Dosage Regimen  
Formulation  
Mode of 
Administration  ORMD -0801  
460 IU (16 mg)  total 
Once daily, twice daily, or three times daily  
Soft gel capsules , 2 capsules per dose  
Oral 
Primary Objective   To compar e pre -treatment (Day 3) to  end of  treatmen t (Day 8) 
24-hour CGM glucose for single and multiple doses of  ORMD -
0801 vs placebo.  
 To evaluate safety parameters for single and multiple doses of  
ORMD -0801 vs placebo.   
Secondary 
Objectives   To compar e pre -treatment (Day 3) to  end of  treatment (Day 8) 
mean daytime CGM glucose for single and multiple doses of  
ORMD -0801 vs placebo.  
 To compar e pre -treatment (Day 3) to  end of  treatment (Day 8) 
mean nighttime CGM glucose for single and multiple doses of  
ORMD -0801 vs placebo.  
 To compare pre -treatment (Day 3) to post -treatment washout 
(Day 9) 24 -hour CGM glucose for single and multiple doses of  
ORMD -0801 vs placebo.  
 To compare post -prandial glucose measurements for single and 
multiple doses of  ORMD -0801 vs placebo.  
 To compare pre-treatment (Day 3) to  end of  treatment (Day 8)  
insulin pharmacokinetics (PK ) for single and multiple doses of  
ORMD -0801 vs placebo.  
 To compare pre-treatment (Day 3) to end of treatment  (Day 8) 
C-peptide pharmacodynamics ( PD) for single and multiple 
doses of  ORMD -0801 vs placebo.  
 To compare defined events of hy poglycemia  for single and 
multiple doses of  ORMD -[ADDRESS_427174] will be randomized to a 
treatment sequence that will include three treatment assignments for 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 5 
CONFIDENTIAL   
 
 each of three treatment Periods according to t he randomization scheme . 
All subjects will receive placebo plus two of the following:  ORMD -
0801 460 IU qd, ORMD-0801  bid, or ORMD -0801  tid.  Subjects will 
receive the randomized treatment from Day 4 through Day 8. A 24 -
hour single -blind placebo washout will be done on Day 9.  For all 
treatment P eriods, pre-treatment CGM data will be collected for  
approximately  36 hours  prior to treatment (Days 1 -3). The cannula will 
be changed and the monitor will remain in place until the morning of 
Day 10 . Blood samples for PD analysis will be taken pre -treatment 
(Day 3) and at end of treatment  (Day 8) to check for concentrations of 
insulin and C -peptide in the blood.  In addition, adverse events, clinical 
laboratory values, vital signs, and ECGs will be evaluated periodically 
for safety. Subjects will be discharged on the morning of Day 10. Each 
treatment Period will be separated by a [ADDRESS_427175] -prandial glucose.  
 
Pharmac okinetics/ Pharmacodynamics will be used to compare pre -
treatment and post -treatment C -peptide and insulin levels.  
Duration of 
Participation  Subjects will be evaluated for parti cipation in the study during a 7 -10 
day Screening period. The planned length of participation is about 65 
days (from Visit 2 through Visit 3). During each  Visit [ADDRESS_427176] Selection 
Criteria  This study will enrol l T2DM subjects with an HbA 1c ≥7.5% and 
≤10.5%, who are taking metformin only, metformin in addition to 
sulfonylurea, metformin in addition to TZD, metformin in addition to 
an SGLT -2 inhibitor, or metformin in addition to a DPP -4 inhibitor 
with all treatment regimens stable for a minimum of 8 weeks prior to 
Visit 2/Period 1/Day 1 . 
Statistical Methods  Pharmacokinetics/ Pharmacodynamics  (PK/PD)  
The PK/PD analysis will be conducted using model -independent 
methods and will be based o n plasma concentrations of insulin and C -
peptide . 
Continuous Glucose Monitoring  
The placebo adjusted change in means will be analyzed using an 
Analysis of Variance (ANOVA) with treatment as the main effect to 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427177] will also be derived to estimate the 
magnitude of the dose response.  
Summary statistics will be presented for both the placebo adjusted 
change in means and the ratios of the placebo adjusted change in 
means . Analysis results will be pre sented for the change in means.  
Safety  
All safety parameters will be summarized and listed using descriptive 
statistics.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427178] OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ .......... 11 
1 INTRODUCTION  ................................ ................................ ................................ ........... 13 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ....15 
2.1 Primar y Objectives ................................ ................................ ................................ .15 
2.2 Secondary Objectives ................................ ................................ ............................. 15 
3 INVESTIGATIONAL PLAN  ................................ ................................ .......................... 15 
3.1 Overall Study Design and Plan  ................................ ................................ .............. 15 
3.2 Screening (7 to 10 Days prior to Visit 2)  ................................ ............................... 16 
3.2.1  Screen Failure  ................................ ................................ .............................. 17 
3.3 Visit 2 (Treatment Per iods 1, 2, and 3)  ................................ ................................ ..17 
3.3.1  Period 1  ................................ ................................ ................................ ........ 17 
[IP_ADDRESS]  Day 1  ................................ ................................ ................................ ..17 
[IP_ADDRESS]  Day 2  ................................ ................................ ................................ ..18 
[IP_ADDRESS]  Day 3  ................................ ................................ ................................ ..18 
[IP_ADDRESS]  Day 4  ................................ ................................ ................................ ..19 
[IP_ADDRESS]  Days 5 -7 ................................ ................................ ............................. 19 
[IP_ADDRESS]  Day 8  ................................ ................................ ................................ ..20 
[IP_ADDRESS]  Day 9  ................................ ................................ ................................ ..20 
[IP_ADDRESS]  Day 10  ................................ ................................ ................................ 21 
3.3.2  Period 2  ................................ ................................ ................................ ........ 21 
[IP_ADDRESS]  Day 1  ................................ ................................ ................................ ..21 
[IP_ADDRESS]  Day 2  ................................ ................................ ................................ ..21 
[IP_ADDRESS]  Day 3  ................................ ................................ ................................ ..22 
[IP_ADDRESS]  Day 4  ................................ ................................ ................................ ..23 
[IP_ADDRESS]  Days 5 -7 ................................ ................................ ............................. 23 
[IP_ADDRESS]  Day 8 ................................ ................................ ................................ ..23 
[IP_ADDRESS]  Day 9  ................................ ................................ ................................ ..24 
[IP_ADDRESS]  Day 10  ................................ ................................ ................................ 24 
3.3.3  Period 3  ................................ ................................ ................................ ........ 25 
[IP_ADDRESS]  Day 1  ................................ ................................ ................................ ..25 
[IP_ADDRESS]  Day 2  ................................ ................................ ................................ ..25 
[IP_ADDRESS]  Day 3  ................................ ................................ ................................ ..26 
[IP_ADDRESS]  Day 4  ................................ ................................ ................................ ..26 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 8 
CONFIDENTIAL  [IP_ADDRESS]  Days 5 -7 ................................ ................................ ............................. 27 
[IP_ADDRESS]  Day 8  ................................ ................................ ................................ ..27 
[IP_ADDRESS]  Day 9  ................................ ................................ ................................ ..28 
[IP_ADDRESS]  Day 10  ................................ ................................ ................................ 28 
3.4 Follow -up Visit (Visit 3, 7 to 9 Days after the end of Visit 2, Period 3)  ............... 28 
3.5 Early Withdraw al (EW)  ................................ ................................ ......................... [ADDRESS_427179] and Trial Discontinuation  ................................ ................................ ......... 35 
5 STUDY TREATMENT  ................................ ................................ ................................ ...37 
5.1 Description of Investigational Drug ................................ ................................ .......37 
5.1.1  Packaging and Labeling  ................................ ................................ ............... 37 
5.1.2  Storage and Handling  ................................ ................................ ................... 38 
5.2 Randomization  ................................ ................................ ................................ .......38 
5.3 Study Treatment Administration ................................ ................................ ............ 38 
5.3.1  Study Treatment Periods  ................................ ................................ .............. 38 
[IP_ADDRESS]  Single -Blind Placebo Administration  ................................ ................ 38 
[IP_ADDRESS]  Double -Blind Treatment Administration  ................................ ........... [ADDRESS_427180] Compliance  ................................ ................................ ............. 39 
5.5.1  Study Treatment Periods 1 and 2  ................................ ................................ .39 
5.6 Drug Accountability ................................ ................................ ............................... 39 
5.7 Concomitant Medications and Supplements  ................................ .......................... 40 
5.8 Dietary Restrictions  ................................ ................................ ............................... 40 
6 STUDY PROCEDURES AND A SSESSMENTS  ................................ ........................... 42 
6.1 Informed Consent ................................ ................................ ................................ ...42 
6.2 Medical History and Prior Medications  ................................ ................................ .42 
6.3 Safety Assessments  ................................ ................................ ................................ 42 
6.3.1  Weight and Height  ................................ ................................ ....................... 42 
6.3.2  Vital Signs  ................................ ................................ ................................ ....42 
6.3.3  Physical Examination ................................ ................................ ................... 42 
6.3.4 12-Lead ECG  ................................ ................................ ............................... 42 
6.3.5  Clinical Laboratory Tests  ................................ ................................ ............. 43 
[IP_ADDRESS]  Clinical Safety Labs  ................................ ................................ ........... 43 
[IP_ADDRESS]  Pregnancy Test  ................................ ................................ ................... 44 
[IP_ADDRESS]  Additional Screening Bloodwork  ................................ ...................... 44 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 9 
CONFIDENTIAL  [IP_ADDRESS]  Drugs of Abuse and Breathalyzer  ................................ ...................... 44 
6.4 Efficacy Assessments ................................ ................................ ............................. 44 
6.4.1  Continuous Glucose Monitors (CGM) ................................ ......................... 44 
6.5 Pharmacokinetic/Pharmacodynamic Assessments  ................................ ................ 45 
6.6 Review and Documentation of Medications and Supplements  ............................. 45 
7 ADVERSE EVENTS AND S AFETY REPORTING ................................ ...................... 46 
7.1 Safety and Tolerability Assessments  ................................ ................................ .....46 
7.2 Definition of Adverse Event  ................................ ................................ .................. 46 
7.3 Definition of Serious Adverse Event  ................................ ................................ .....46 
7.3.1  Adverse Events of Hypoglycemia  ................................ ............................... 47 
7.4 Eliciting and Reporting of Adverse Events  ................................ ........................... 47 
7.4.1  Routine Reporting of Adverse Events  ................................ ......................... 47 
7.4.2  Reporting of Serious Adverse Events, Including D eath .............................. 48 
7.5 Causality Assessment of Adverse Events  ................................ .............................. 50 
7.5.1  Potential Adverse Events Associated with ORMD -0801  ............................ 50 
7.6 Adverse Event Severity Assessment  ................................ ................................ ......51 
7.7 Expectedness of Adverse Event  ................................ ................................ ............. 51 
7.8 Assessment of Adverse Event Outcome  ................................ ................................ 51 
7.9 Clinical Findings  ................................ ................................ ................................ ....52 
8 STATISTICAL METHODS  ................................ ................................ ............................ 52 
8.1 Sample Size  ................................ ................................ ................................ ............ 52 
8.2 Pharmacokinetic/Pharmacodynamic Evaluation  ................................ ................... 52 
8.3 Continuous Glucose Monitor Evaluation ................................ ............................... 52 
8.4 Safety Evaluation  ................................ ................................ ................................ ...53 
8.4.1  Safety Population  ................................ ................................ ......................... 53 
8.4.2  Adverse Events  ................................ ................................ ............................ 53 
8.4.3  Laboratory Evaluations  ................................ ................................ ................ 54 
8.4.4  Vital Signs  ................................ ................................ ................................ ....54 
8.4.5  12-lead ECG ................................ ................................ ................................ .54 
8.4.6  Phys ical Examination ................................ ................................ ................... 54 
8.4.7  Prior and Concomitant Medications and Supplements  ................................ 54 
8.4.8  Handling of Missing, Unused, or Spurious Data  ................................ ......... 55 
9 DATA MANAGEMENT ................................ ................................ ................................ .56 
9.1 Data Collection  ................................ ................................ ................................ ......56 
9.2 Electronic Data Capture  ................................ ................................ ......................... 56 
9.3 Quality Assurance and Database Lock  ................................ ................................ ..56 
10 AMENDMENTS/MODIFICAT IONS OF THIS PROTOCO L................................ .......56 
11 INVESTIGATOR OBLIGAT IONS  ................................ ................................ ................ 57 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427181] Confidentiality  ................................ ................................ .......................... 59 
11.3  Case Report Forms  ................................ ................................ ................................ .59 
11.4  Source Documentation  ................................ ................................ ........................... 59 
11.5  Retention of Records ................................ ................................ .............................. 59 
11.6 Clinical Study Report  ................................ ................................ ............................. 60 
12 STUDY ADMINISTRATION ................................ ................................ ......................... 60 
12.1  Study Monitoring  ................................ ................................ ................................ ...60 
12.2  On-Site Audits  ................................ ................................ ................................ .......61 
12.3  Data Quality Assurance  ................................ ................................ ......................... 61 
12.4  Publication Policy  ................................ ................................ ................................ ..61 
12.5  Disclosure and Confidentiality  ................................ ................................ .............. 62 
13 REFERENCES  ................................ ................................ ................................ ................ 63 
 
  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427182] of 1996  
HIV  Human Immunodeficiency Virus  
HR  heart rate  
IB  Investigator's Brochure  
ICF  informed consent form 
ICH  International Council for  Harmoniz ation  
IND  Investigational New Drug application  
IRB  Institutional Review Board  
IUD  intrauterine device  
MedDRA  Medical Dictionary for Regulatory Activities  
PD  Pharm acodynamic  
PI  [INVESTIGATOR_344243]  
T2DM   Type [ADDRESS_427183]  upper limit of normal  
WCBP   woman of childbearing potential  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 12 
CONFIDENTIAL  WHO   World Health Organization  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427184] 8% of the U.S. population in 2007, and worldwide (Centers for 
Disease Control and Prevention, 2008).  Diabetes mellitus is defined  by [CONTACT_157710] (increased 
concentration of glucose in the blood) caused by [CONTACT_344256] (type  1), resistance 
to insulin action (type 2), or a combination of both.  Diabetes mellitus leads to an increased risk 
of microvascular damage (retin opathy, nephropathy and neuropathy), reduced life expectancy, 
increased risk of macrovascular complications (ischemic heart disease, stroke, and peripheral 
vascular disease), and diminished quality of life.  This illness requires continuing medical care 
and patient self -management and education to prevent acute complications and to reduce the risk 
of long -term complications (American Diabetes Association, 2009).  
The World Health Organization has established diagnosis criteria for type 2 diabetes mellitus 
(T2DM) of fasting plasma glucose greater than or equal to 126 mg/dL (7.0  mmol/L), plasma 
glucose greater than or equal to 200 mg/dL (11.1 mmol/L) at [ADDRESS_427185], or random plasma gluc ose greater than 200 
mg/dL (11.1 mmol/L) in a person with symptoms of diabetes (World Health Organization, 
2006).  The treatment goal for patients with this disease is long -term glycemic control (over both 
fasting and non -fasting blood glucose levels), which has been demonstrated in both type 1 and 
type 2 patients to reduce the morbidities associated with uncontrolled glycemic levels (Diabetes 
Control and Complications Trial Research Group, 1993; Cleary et al., 2006; [LOCATION_006] Prospective 
Diabetes Study Group, 1998a & 1998b). Typi[INVESTIGATOR_344244] 
T2DM include lifestyle management (diet and exercise), exogenously administered insulin, 
insulin plus oral drugs such as metformin or sulfonylureas, and oral drugs alone.  Glycemic 
contro l is measured by [CONTACT_18654] -monitoring of blood glucose (SMBG), patient self -monitoring 
of interstitial glucose, and periodic blood tests for measurement of hemoglobin A1C (HbA1 c). 
HbA1 c levels reflect average glycemia over several months and therefore p rovide a surrogate for 
glycemic control (U.S. Food and Drug Administration, 2008).  A consensus statement written by 
[CONTACT_344257]1 c level of <7% as an objective for n onpregnant adults, who do not have 
complicating factors, for the prevention of micro - and macrovascular disease (Nathan et  al., 
2009 ). 
In addition to lifestyle modification through diet and exercise, a number of treatments are 
available to treat hyperglyce mia in diabetic patients.  The choice of antihyperglycemic agents is 
made between physicians and patients based upon the agents’ effectiveness in lowering glucose, 
other effects that can reduce long -term complications, safety, tolerability, ease of use, and  
expense.  For example, metformin is widely prescribed as an initial therapy to improve glycemic 
control in patients with T2DM.  It decreases hepatic glucose output and lowers fasting glycemia, 
thereby [CONTACT_344258]1 c levels.  It is generally well -tolerated, w ith possible gastrointestinal 
adverse events and low incidence of hypoglycemia, but is contraindicated in patients with renal 
dysfunction.  Sulfonylureas lower glycemia by [CONTACT_344259], and are effective in 
lowering HbA1 c levels.  Possible adv erse events associated with this class of drugs include 
hypoglycemia (more frequent in elderly patients) and weight gain.  Other drugs such as 
thiazolidinediones (TZDs), Glucagon -Like Peptide 1( GLP-1) analogue, α -glucosidase inhibitors, 
glinides, and pramli ntide are commercially available in the U.S., but are considered less well -
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427186] -effectiveness for achieving target 
glycemic goals than lifestyle management, metformin, and sulfonylureas (Nathan et al ., 2009).  
Subcutaneously administered insulin is highly effective at lowering glycemia and helpi[INVESTIGATOR_344245]1 c levels.  Insulin has no overall dose limit with respect to safety and 
provides an improved lipid profile.  However, subcutane ously administered insulin requires daily 
injections and blood glucose monitoring, and is associated with weight gain and an increased risk 
of hypoglycemia.  Insulin is available as formulations with different pharmacokinetic (PK) and 
pharmacodynamic (PD) profi les (e.g, rapid, regular, intermediate, or long acting, or mixtures of 
these).  These different formulations are used (Nathan et al., 2006) to tailor appropriate insulin 
regimens on a per patient basis . 
Oramed Ltd. is developi[INVESTIGATOR_007] a proprietary oral formulati on of recombinant human insulin 
(ORMD -0801).  Oramed, located in Jerusalem, Israel, was established in 2006 and the company’s 
proprietary platform technology is based on over [ADDRESS_427187] in Oramed’s pi[INVESTIGATOR_19189], the pi[INVESTIGATOR_344246], and a 
GLP -1 analogue.   
ORMD -0801 is based on Oramed’s platform technology for the oral delivery of polypeptides , 
which includes a proprietary formulation of excipi[INVESTIGATOR_344247], and into the systemic circulation.  The formulati on for ORMD -0801 includes 
aprotinin and soybean trypsin inhibitor (SBTI) to hinder proteolysis, and disodium 
ethylenediaminetetraacetic acid ( EDTA ) to facilitate translocation.  The fish oil provides omega -[ADDRESS_427188].  Thus, oral insulin administration is expected to  avoid systemic 
hyperinsulinemia and provid e a markedly reduced risk of hypoglycemia.  he PK/PD profile of 
ORMD -[ADDRESS_427189] of ORMD -0801 on glucose as measured by [CONTACT_344260] a ten 
day treatment period with three doses per day prior to meals. Notably, one Phase 2 study 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 15 
CONFIDENTIAL  assessed the safety and e ffectiveness  on fasting blood glucose of repeat bed time administration 
of ORMD -0801 in patient s with type 2 diabetes over a period of 6 weeks . A Phase 1/[ADDRESS_427190] is well -
tolerated and can effectively reduce plasma glucose and C -peptide levels.  There were no 
significant safety observations and no serious adverse reactions were reported for the completed 
studies, although there were two self -reported events of hypoglycemia in t he six -week, Phase 2 
study.  
Oramed intends to continue with clinical development of ORMD -0801 under a U.S. IND 
application.   
 
2 STUDY OBJECTIVES  
2.1 Primary Objective s 
 To compare pre -treatment (Day 3) to  end of  treatment (Day 8) 24 -hour CGM glucose for 
single a nd multiple doses of ORMD -0801 vs placebo.  
 To evaluate safety parameters for single and multiple doses of  ORMD -0801 vs placebo.  
2.2 Secondary Objectives  
 To compare pre -treatment (Day 3) to  end of  treatment (Day 8) mean daytime CGM 
glucose for single and multiple doses of ORMD -0801 vs placebo.  
 To compare pre -treatment (Day 3) to  end of  treatment (Day 8) mean nighttime CGM 
glucose for single and multiple doses of ORMD -0801 vs placebo.  
 To compare pre -treatment (Day 3) to post -treatment washout (Day 9) 24 -hour CGM 
glucose for single and multiple doses of ORMD -0801 vs placebo.  
 To compare post -prandial glucose measurements for single and multiple doses of  
ORMD -0801 vs placebo.  
 To compare pre-treatment (D ay 3) to end of treatment (Day 8)  insulin pharmacokinetics 
(PK)  for single and multiple doses of  ORMD -0801 vs placebo.  
 To compare pre-treatment (Day 3) to end of treatment  (Day 8) C -peptide 
pharmacodynamics (PD)  for single and multiple doses of  ORMD -0801 v s placebo.  
 To compare defined events of hypoglycemia for single and multiple doses of  ORMD -
[ADDRESS_427191] will be randomized to a treatment sequence that will include three 
treatment assignments for each of three treatment Periods acc ording to t he randomization 
scheme . All subjects will receive placebo plus two of the following:  ORMD -[ADDRESS_427192] -0801  bid, or ORMD -0801  tid.  Subjects will receive the randomized treatment from Day 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 16 
CONFIDENTIAL  4 through Day 8. A 24 -hour single -blind placebo  washout will be done on Day 9.  For all 
treatment P eriods, pre -treatment CGM data will be collected for approximately 36 hours  prior to 
treatment (Days 1 -3). The cannula will be changed and the monitor will remain in place 
throughout the 5 -day treatment p eriod (Days 4 -8) and for an additional [ADDRESS_427193] -treatment 
(Day 9). Blood samples for PD analysis will be taken pre -treatment (Day 3) and at end of 
treatment  (Day 8) to check for concentrations of insulin and C -peptide in the blood.  In addition, 
adver se events, clinical laboratory values, vital signs, and electrocardiograms ( ECGs ) will be 
evaluated periodically for safety. Subjects will be discharged on the morning of Day 10. Each 
treatment Period will be separated by a [ADDRESS_427194]  treatment period .  
3.2 Screening (7 to 10 Days prior to Visit 2 ) 
At the S creening  Visit , potential subjects will be given  a detailed oral presentation describing the 
nature, purpose, risks, and requir ements of the study and will also receive  detailed written 
information  (ICF).  They will have adequate opportunity to ask the appropriate person of the 
Investigational  staff (i.e., Principal Investigator [INVESTIGATOR_1461]) presenting the study about any 
aspect o f the study.   
Once the subject is satisfied that he/she is willing to participate in the study, he/she will be a sked 
to sign the study ICF (refer to Section 11.1.4  for further detail regarding the ICF).  The 
Investigational Site  personnel obtaining written consent from the subject will also sign the form 
to confirm consent has been obtained.  
Once signed, the Investigator will retain the original ICF for the subject’s study records and 
provide the subject with a signed copy.  The Investigator will verify that informed consent has 
been obtained from each subject prior to enrollment  into the study and prior to the subject 
undergoing any study -related procedures.  
Screening activities subsequent to obtaining informed consent will be conducted and consist of 
the following:  
 Completion of medical and social history , including  tobacco, alcohol, caffeine, and drug 
use; 
 Collection of demographic data (sex, age, race/ethnicity) ; 
 Review of prior  and current medications  and supplements;  
 Review  inclusion and exclusion criteria;  
 Physical examination;  
 12-lead ECG;  
 Measurement of vital signs (height, weight, seated SBP/ DPB, and heart rate ); 
 Perform breathalyzer;  
 Collection of fasted  blood and urine samples for:  
o Clinical safety labs, including hemat ology, serum chemistry  (with HbA1c, C -peptide, 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 17 
CONFIDENTIAL  and TSH) , and urinalysis  (see Section  6.3.[ADDRESS_427195] of tests ); 
o Urine drug screen;  
o Serum  pregnancy test (WCBP only);  
o Serum FSH (to test for women in early menopause);  
For subjects who meet eligibility criteria based on the Screening  assessments, instruct as follows:  
 Use adequate contraceptive methods (see Section 4.1) for the duration of the study 
(Screening through Follow -Up Visit 3); 
 Keep the  use of concomitant medications at a minimum  during the study , if possible , and 
avoid prohibited medications as defined in Section 5.7; 
 Maintain their usual dietary habits for the periods of the study where they will not be 
housed in the CRU and avoid drastic changes, such as a conversion to a vegetarian diet;  
 Refrain from any unusual or unaccustomed vigorous exercise during the course of the 
study;  
 Refrain from excessive alcohol use or binge drinking during the study, and not to drink 
alcohol from 72 hours prior to admission to the CRU ( Visit 2/ Day 1) thru discharge from 
the CRU;  
 Refrain from excessive caffeine use (i.e., more than five cups of caffeinated beverages 
per day) during the course of the study;  
 
3.2.[ADDRESS_427196] who has signed the ICF, does  not meet all the entry 
criteria outlined in Section 4  of this protocol  (note that this includes assessments through Visit 
2/Day 1), and was not randomized to receive study treatment (active or placebo) . 
The Investigator is responsible for keepi[INVESTIGATOR_007] a record  of all subjects screened for entry into the 
study and subsequently excluded.  The reason(s) for exclusion will be recorded in the source 
documents and on the Screening log.  
3.3 Visit 2 (Treatment Periods 1, 2, and 3 ) 
3.3.1  Period 1  
Subjects will report to the CRU on the morning of  Day 1.  
[IP_ADDRESS]  Day 1  
 Review of medical history;  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/ DPB, and heart rate ); 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 18 
CONFIDENTIAL   Provide  the first dose of single -blind placebo at least [ADDRESS_427197];  
 Provide breakfast;  
 Subjects will be fitted with the continuous glucose monitoring (CGM) device and data 
recording will begin;  
 Provide  4 doses  (8 capsules)  of sin gle-blind placebo and instruct subjects  to take one dose 
at least [ADDRESS_427198] 45 minutes before lunch on Day 2.  
 Adverse events will be monitored and recorded.  
 Subjects will be instructed to return to the CRU at approximately 5pm (±30 minutes) on 
Day 2.  
[IP_ADDRESS]  Day 2  
 Admission to the CRU at approximately 5pm (±30 minutes);  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, heart rate, and temperature);  
 Perform breathalyzer;  
 Collect a urine sample for:  
o Drug screen;  
o Pregnancy testing (WCBP only)  
 Provide  a standardized diabetic meal at approximately 7pm (±  60 minutes).  Standardized 
meals will continue throughout the remainder of the study Period.  
 Provide a dose of single -blind placebo at approximately 10pm ( ± 60 minutes) . 
 Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 3  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/D PB, heart and rate ); 
 Provide a dose of single -blind placebo  at approximately 7am (± 60 minutes);  
 Provide breakfast no sooner than 45 minutes after the morning dose ; 
 Provide a dose of single -blind placebo  at approximately 1pm (± 60 minutes),  at least 45 
minutes prior to lunch;  
 Provide lunch no sooner than 45 minutes after the afternoon dose ; 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 19 
CONFIDENTIAL   Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of single -blind placebo at approximately 10pm (± 60 minutes);  
 Collect a blood sample according to schedule (per randomization scheme , either morning, 
afternoon, or evening ) prior to the specified dose of placebo for : 
o Pre-dose PD analysis  
o Serum chemistry  
 Collect  scheduled (per randomization scheme)  postdose PD blood draws every 30 
minutes (± 5 minutes ) until 5 hours has elapsed ; 
 Replace the CGM cannula at app roximately 7pm (± 60 minutes), such that it does not 
interfere with any post -dose PD blood draws;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 4  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/ DPB, and heart rate ); 
 Randomization  
 Provide a dose of study treatment or placebo  at approximately 7am (± 60 minutes);  
 Provide breakfast no sooner than 45 minutes after the morning dose ; 
 Provide a dose of study treatment or placebo  at approximately 1pm (± 60 minutes),  at 
least 45 minutes prior to lunch;  
 Provide lunch no sooner than 45 minutes after the afternoon dose;  
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of study  treatment or placebo at approximately 10pm (± 60 minutes) ; 
 Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Days 5 -7 
 Review of medications and supplements;  
 Measurement of vital signs (weight,  seated SBP/DPB, and heart rate ); 
 Provide a dose of study treatment or placebo  at approxi mately 7am (± 6 0 minutes) ; 
 Provide br eakfast no sooner than 45 minutes after the morning dose ; 
 Provide a dose of study treatment or placebo  at approximately 1pm (± 60 minutes);  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 20 
CONFIDENTIAL   Provide lunch no sooner than 45 minutes after the afternoon dose ; 
 Provide dinner at approximately 7pm (± 60 minutes) ; 
 Provide a dose of study treatment or placebo at approximately 10pm (± 60 minutes) ; 
 Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 8 
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB,  and heart rate);  
 Provide a dose of study treatment or placebo at approximately 7am (± 60 minutes);  
 Provide breakfast no sooner than 45 minutes after the morning dose ; 
 Provide a dose of study treatment or placebo  at approximately 1pm (± 60 minutes);  
 Provid e lunch no sooner than 45 minutes after the afternoon dose ; 
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of study treatment or  placebo at approximately 10pm (± 60 minutes);  
 Collect a blood sample according to schedule (per randomization scheme, either morning, 
afternoon, or evening) prior to the specified dose of placebo for:  
o Pre-dose PD analysis  
o Serum chemistry  
 Collect scheduled (per randomization scheme) postdose PD blood draws every 30 
minutes (± 5 minutes) until 5 hours has elapsed;  
 Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 9  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/ DPB, and heart rate ); 
 Provide a dose of single -blind placebo at approximately 7am (± 60 minut es); 
 Provide breakfast no sooner than 45 minutes after the morning dose ; 
 Provide a dose of single -blind placebo  at approximately 1pm (± 6 0 minutes) ; 
 Provide lunch  no sooner than 45 minutes after the afternoon dose ; 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 21 
CONFIDENTIAL   Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of single -blind placebo at approximately 10pm (± 60 minutes) ; 
 Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 10  
 Review of medications and supplements;  
 Measurement of vital signs (weight,  seated SBP/DPB, and heart rate ); 
 Remove the CGM monitor; download CGM data;  
 Provide breakfast;  
 Adverse events will be monitored and recorded.  
 Subjects will be discharged for a minimum 2 -week washout period.  
3.3.2  Period 2  
Subjects will report to the CRU on the  morning of Day 1.  
[IP_ADDRESS]  Day 1  
 Review of medical history;  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Provide the first dose of single -blind placebo at least [ADDRESS_427199];  
 Provide b reakfast;  
 Subjects will be fitted with the continuous glucose monitoring (CGM) device and data 
recording will begin;  
 Provide [ADDRESS_427200] 45 minutes before lunch on Day 2.  
 Adverse events will be monitored and recorded.  
 Subjects will be instructed to return to the CRU at approximately 5pm (±30 minutes) on 
Day 2.  
[IP_ADDRESS]  Day 2  
 Admission to the CRU at approximately 5pm (±30 minutes);  
 Review of medications and supplements;  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 22 
CONFIDENTIAL   Measurement of vital signs (weight, seated SBP/DPB, heart rate, and temperature);  
 Perform breathalyzer;  
 Collect a urine sample for:  
o Drug screen;  
o Pregnancy testing (WCBP only)  
 Provide a standardized diabetic meal at approximately 7pm (± 60 minutes).  Standardized 
meals will continue throughout the remainder of the study Period.  
 Provide a dose of single -blind placebo at approximately 10pm (± 60 minutes).  
 Conti nue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 3  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, heart and rate);  
 Provide a dose of single -blind placebo at approximately 7am (± 60 minutes);  
 Provide breakfast no sooner than 45 minutes after the morning dose;  
 Provide a dose of single -blind placebo  at approximately 1pm (± 60 minutes), at least 45 
minutes prior to lunch;  
 Provide lunch no sooner than 45 minutes after the afternoon dose;  
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of single -blind placebo at approximately 10pm (± 60 minutes);  
 Collect a blood sample according to schedule (per randomization scheme, either morning, 
afternoon, or evening) prior to the specified d ose of placebo for:  
o Pre-dose PD analysis  
o Serum chemistry  
 Collect scheduled (per randomization scheme) postdose PD blood draws every 30 
minutes (± 5 minutes) until 5 hours has elapsed;  
 Replace the CGM cannula at approximately 7pm (± 60 minutes), such that i t does not 
interfere with any post -dose PD blood draws;  
 Adverse events will be monitored and recorded.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 23 
CONFIDENTIAL  [IP_ADDRESS]  Day 4  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Randomization  
 Provide a dose of study treatment or placebo  at approximately 7am (± 60 minutes);  
 Provide breakfast no sooner than 45 minutes after the morning dose;  
 Provide a dose of study treatment or placebo  at approximately 1pm (± 60 minutes), at 
least 45 minutes prior to lunch;  
 Provide lunc h no sooner than 45 minutes after the afternoon dose;  
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of study treatment or placebo at approximately 10pm (± 60 minutes);  
 Continue CGM monitoring;  
 Adverse events will be monitored and recor ded. 
[IP_ADDRESS]  Days 5 -7 
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Provide a dose of study treatment or placebo  at approximately 7am (± 60 minutes);  
 Provide breakfast no sooner than 45 minutes after th e morning dose;  
 Provide a dose of study treatment or placebo  at approximately 1pm (± 60 minutes);  
 Provide lunch no sooner than 45 minutes after the afternoon dose;  
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of study treatment or pla cebo at approximately 10pm (± 60 minutes);  
 Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 8  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Provide a dose of study tre atment or placebo at approximately 7am (± 60 minutes);  
 Provide breakfast no sooner than 45 minutes after the morning dose;  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 24 
CONFIDENTIAL   Provide a dose of study treatment or placebo  at approximately 1pm (± 60 minutes);  
 Provide lunch no sooner than 45 minutes after the a fternoon dose;  
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of study treatment or  placebo at approximately 10pm (± 60 minutes);  
 Collect a blood sample according to schedule (per randomization scheme, either morning, 
afternoon, or evening) prior to the specified dose of placebo for:  
o Pre-dose PD analysis  
o Serum chemistry  
 Collect scheduled (per randomization scheme) postdose PD blood draws every 30 
minutes (± 5 minutes) until 5 hours has elapsed;  
 Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 9  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Provide a dose of single -blind placebo at approximately 7am (± 60 minutes);  
 Provide breakfast no sooner than 45 minute s after the morning dose;  
 Provide a dose of single -blind placebo at approximately 1pm (± 60 minutes);  
 Provide lunch no sooner than 45 minutes after the afternoon dose;  
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of single -blind place bo at approximately 10pm (± 60 minutes);  
 Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 10  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Remove the CGM monitor; down load CGM data;  
 Provide breakfast;  
 Adverse events will be monitored and recorded.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 25 
CONFIDENTIAL   Subjects will be discharged for a minimum 2 -week washout period.  
3.3.3  Period 3  
Subjects will report to the CRU on the morning of Day 1.  
[IP_ADDRESS]  Day 1  
 Review of medical history;  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Provide the first dose of single -blind placebo at least [ADDRESS_427201];  
 Provide breakfast;  
 Subjects will be fitted with the continuous glucose monitoring (CGM) device and data 
recording will begin;  
 Provide [ADDRESS_427202] 45 minutes before lunch on Day 2.  
 Adverse events will be monitored and recorded.  
 Subjects will be instructed to return to the CRU at approximately 5pm (±30 minutes) on 
Day 2.  
[IP_ADDRESS]  Day 2  
 Admission to the CRU at approximately 5pm (±30 minutes);  
 Review  of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, heart rate, and temperature);  
 Perform breathalyzer;  
 Collect a urine sample for:  
o Drug screen;  
o Pregnancy testing (WCBP only)  
 Provide a standardized diabetic meal at approxim ately 7pm (± 60 minutes).  Standardized 
meals will continue throughout the remainder of the study Period.  
 Provide a dose of single -blind placebo at approximately 10pm (± 60 minutes).  
 Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 26 
CONFIDENTIAL  [IP_ADDRESS]  Day 3  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, heart and rate);  
 Provide a dose of single -blind placebo at approximately 7am (± 60 minutes);  
 Provide breakfast no sooner than 45 minutes after the morning dose ; 
 Provide a dose of single -blind placebo  at approximately 1pm (± 60 minutes), at least 45 
minutes prior to lunch;  
 Provide lunch no sooner than 45 minutes after the afternoon dose;  
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of single -blind placebo at approximately 10pm (± 60 minutes);  
 Collect a blood sample according to schedule (per randomization scheme, either morning, 
afternoon, or evening) prior to the specified dose of placebo for:  
o Pre-dose PD analysis  
o Serum chemistry  
 Collect sch eduled (per randomization scheme) postdose PD blood draws every 30 
minutes (± 5 minutes) until 5 hours has elapsed;  
 Replace the CGM cannula at approximately 7pm (± 60 minutes), such that it does not 
interfere with any post -dose PD blood draws;  
 Adverse even ts will be monitored and recorded.  
[IP_ADDRESS]  Day 4  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Randomization  
 Provide a dose of study treatment or placebo  at approximately 7am (± 60 minutes);  
 Provide bre akfast no sooner than 45 minutes after the morning dose;  
 Provide a dose of study treatment or placebo  at approximately 1pm (± 60 minutes), at 
least 45 minutes prior to lunch;  
 Provide lunch no sooner than 45 minutes after the afternoon dose;  
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of study treatment or placebo at approximately 10pm (± 60 minutes);  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 27 
CONFIDENTIAL   Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Days 5 -7 
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Provide a dose of study treatment or placebo  at approximately 7am (± 60 minutes);  
 Provide breakfast no sooner than 45 minutes after the morning dose;  
 Provide a dose of study treatment or placebo  at appr oximately 1pm (± 60 minutes);  
 Provide lunch no sooner than 45 minutes after the afternoon dose;  
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of study treatment or placebo at approximately 10pm (± 60 minutes);  
 Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 8  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Provide a dose of study treatment or placebo at approximately 7am (± 60 minutes);  
 Provide break fast no sooner than 45 minutes after the morning dose;  
 Provide a dose of study treatment or placebo  at approximately 1pm (± 60 minutes);  
 Provide lunch no sooner than 45 minutes after the afternoon dose;  
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of study treatment or placebo at approximately 10pm (± 60 minutes);  
 Collect a blood sample according to schedule (per randomization scheme, either morning, 
afternoon, or evening) prior to the specified dose of placebo for:  
o Pre-dose PD analysis  
o Serum chemistry  
 Collect scheduled (per randomization scheme) postdose PD blood draws every 30 
minutes (± 5 minutes) until 5 hours has elapsed;  
 Continue CGM monitoring;  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 28 
CONFIDENTIAL   Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 9  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Provide a dose of single -blind placebo at approximately 7am (± 60 minutes);  
 Provide breakfast no sooner than 45 minutes after the morning dose;  
 Provide a dose of single -blind placebo at a pproximately 1pm (± 60 minutes);  
 Provide lunch no sooner than 45 minutes after the afternoon dose;  
 Provide dinner at approximately 7pm (± 60 minutes);  
 Provide a dose of single -blind placebo at approximately 10pm (± 60 minutes);  
 Continue CGM monitoring;  
 Adverse events will be monitored and recorded.  
[IP_ADDRESS]  Day 10  
 Review of medications and supplements;  
 Measurement of vital signs (weight, seated SBP/DPB, and heart rate);  
 Remove the CGM monitor; download CGM data;  
 Provide breakfast;  
 Adverse events will be monitored a nd recorded.  
 Subjects will be discharged until the 1 -week follow -up visit.  
 
3.4 Follow -up Visit (Visit 3, 7 to 9 Days after the end of Visit 2, Period 3 ) 
Subjects will return to the clinic 7 to 9 days after Visit 2/Day 10 (approximately 65 days since 
the beginning of the study) and the following procedures will be performed:  
 Review of medications and supplements;  
 Vital signs (including weight, seated SBP/ DPB, and heart rate ); 
 Physical examination;  
 Collection of blood and ur ine samples for:  
o Clinical safety labs, including hematology, serum chemistry, and urinalysis  (see 
Section  6.3.[ADDRESS_427203] of tests ); 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 29 
CONFIDENTIAL   Record adverse events;  
 Discharge from the study.  
Any subject with a possible study treatment  related AE at the Follow -Up Visit will be followed 
until resolution or stabilization of the event.  Further, any SAE, whether or not related to study 
treatment , that occurs within [ADDRESS_427204]'s source 
documentation and in the CRF.  
3.5 Early Withdrawal (EW)  
If a randomized subject is withdrawn from the study prior to completing study  treatment, the 
subject will be discharged from the CRU and instructed to return to the clinic the next day and 
the following procedures will be performed:  
 Review of medications and supplements;  
 Vital sign s (including weigh t, seated SBP/DPB, and heart rate ); 
 Physical examination;  
 Collection of blood and urine samples for:  
o Clinical safety labs, including hematology, serum chemistry, and urinalysis  (see 
Section  6.3.[ADDRESS_427205] of t ests); 
 Record adverse events;  
 Discharge from the study.  
If a randomized subject is withdrawn from the st udy prior to completing all three  treatment 
periods , the subject will be discharged from the CRU and instructed to return to the clinic the 
next day for Follow -Up evaluations as performed for Visit 3.  
Any subject with a possible study treatment  related AE at the time of EW will be followed until 
resolution or stabilization of the event.  
3.6 Schedule of Events  
Table 1 below describes the daily schedule of events from Screening  Visit 1  through Follow -Up 
Visit  3.   
 
  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 30 
CONFIDENTIAL  Table 1 : Daily Schedule of Events from Screening Through F ollow -Up Visit  
Visit  Screening  
Visit 1  Treatment Visit 2  
Periods 1, 2, and 3  Follow -Up 
Visit 3  EW 
Study Day  Day -7 to -10 1 2 3 4 5 6 7 8 9 10 ~65 N/A 
Informed Consent  X             
Medical History  X X            
Demographics  X             
Concomitant Medications  X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria  X             
Physical Exam  X           X X 
ECG  X             
Vital Signs1 X X X X X X X X X X X X X 
Hematology/Chemistry/Urinalysis2 X2   X2     X2   X2 X2 
Urine Drug Screen  X  X           
Breathalyzer  X  X           
Serum Pregnancy Test3 X             
Urine Pregnancy Test3   X           
Placebo Administration4  X X X      X    
CGM Monitoring5  X X X X X X X X X    
CRU Admission    X           
Standardized Diabetic Meals6  X X X X X X X X X X   
Pharmacodynam ic Samples7    X     X     
Remove CGM and Download Data            X   
Randomization/Crossover8     X         
Treatment Administration9     X X X X X     
CRU Discharge            X   
Adverse Events   X X X X X X X X X X X X 
Study Disposition             X X 
 
  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 31 
CONFIDENTIAL  1Vital signs incl ude height, weight,  heart rate, systolic BP, and diastolic BP.  Height will be measured at Screening 
only.  Temperature will be measured at Visit 2/Day [ADDRESS_427206] hematology/chemistry/urinalysis, plus  HbA 1c, C-peptide, and TSH.  FSH will 
also be performed for women who are pre -menopausal. On Visit [ADDRESS_427207] 
hematology/chemistry/urinalysis.  
3Pregnancy tests will be performed for women of childbearing potential only.  
4A single dose of placebo will be administered on the morning of Day 1. Subjects will be dispensed the next 4 doses  
(8 capsules ) with dosing instructions. On Day 3 and Day 9, doses will be administered at approximately 7am 
(±60 minutes), 1pm (±60 minutes), and 10pm (±60 minutes).  
5The CGM monitor will be fitted on Day  1, the cannula will be changed  on Day 3  at approximately 7pm (± 60 
minutes) , and the monitor will continue recording measurements until the morning of Day 10.  
6A standardized breakfast will be provided on Day 1. Beginning with dinner on Day [ADDRESS_427208] and lunch will be provided no sooner than 45 minutes after corresponding treatment doses .  
Dinner will be provided at approximately 7pm  (±60 minutes).  Standardized snacks will be provided between 
breakfast and lunch, between lunch and dinner, and between dinner and bedtime.  
7Blood sam ples (scheduled per randomization scheme)  for insulin and C -peptide will be draw n pre-dose and  every 
30 minutes (± 5 minutes) postdose until 5 hours  has elapsed . 
8Randomization will occur on the morning of Period 1/Day 4.  Crossover will occur on the morning of Period 2/Day 
4 and then again on the morning of Period 3/Day 4.  
9Subjects will receive their assigned randomized treatment from the morning of Day 4 through the evening of  Day 8.  
Doses will be administered at approximately 7am (±60 minutes), 1pm (±60 minutes), and 10pm (±60 minutes).  
 
  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427209]  meet all of the following criteria to be eligible for the study:  
1. Male or female subjects, age 20 to 75  years, inclusive with type 2 diabetes mellitus . 
2. At Visit 2 /Period 1/Day 1, subjects will have been treated for their diabetes  by [CONTACT_14424] 
(≥1000 mg/day; any type and regimen), metformin and a DPP -[ADDRESS_427210] been on a stable regimen of metformin (defined as the same metformin  dose and 
type) and other treatments for at least 8 weeks prior to Visit 2/Period 1/Day 1.  
3. Body Mass Index (BMI) between 25 and 40 kg/m2, inclusive, at Screening.  
4. Hemoglobin A1c (HbA 1c) between ≥7 .5 and ≤10.5 % at Screening.  
5. Fasting serum  glucose greater t han or  equal to 126 mg/dL  at Screening.  
6. Females of childbearing potential must have a negative serum pregnancy test result at 
Screening and a negative urine pregnancy test at Visit 2/Day 1 for all study Periods.  
a. Females who are not of childbearing potenti al are defined as :  
i. Postmenopausal (defined as at least 12 months with no menses in women 
≥45 years of age)  
ii. Has had a hysterectomy and/or bilateral oophorectomy, bilateral 
salpi[INVESTIGATOR_1656], or bilateral tubal ligation/occlusion at least 6 weeks prior 
to scree ning; OR  
iii. Has a congenital or acquired condition that prevents childbearing.  
b. Females of childbearing potential agree to avoid becoming pregnant while 
receiving study treatment  and for [ADDRESS_427211] dose of study treatment  by 
[CONTACT_139649]:  
i. practice abstinence† from heterosexual activity OR  
ii. Use (or have her partner use) acceptable contraception during heterosexual 
activity.  Acceptable methods of contraception are‡: 
1. Single method (one of the following is acceptable):  
a. Non-hormonal intrau terine device (IUD)  
b. vasectomy of a female subject’s male partner  
2. Combination method (requires use of two of the following):  
a. diaphragm with spermicide (cannot be used in conjunction 
with cervical cap/spermicide)  
b. cervical c ap with spermicide (nulliparous women only)  
c. contraceptive sponge (nulliparous women only)  
d. male condom or female condom (cannot be used together)  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 33 
CONFIDENTIAL  †Abstinence (relative to heterosexual activity) can be used as the sole method of 
contraception if it is consi stently employed as the subject’s preferred and usual 
lifestyle and if considered acceptable by [CONTACT_176742]/IRBs.  
Periodic abstinence (e.g., calendar, ovulation, sympto -thermal, post -ovulation 
methods, etc.) and withdrawal are not a cceptable methods of contraception.  
‡If a contraceptive method listed above is restricted by [CONTACT_427]/guidelines, 
then it does not qualify as an acceptable method of contraception for subjects 
participating at sites in this country/region.  
4.[ADDRESS_427212] be  excluded from the study:  
1. Usage of anti -diabetic agents other than metformin , sulfonylurea,  SGLT -2 inhibitors, 
TZD, or DPP -4 inhibitors within 6 weeks prior to Visit 2/Period 1/Day 1.  
2. Presence of any clinically significant endocrine disease according to the Investigator 
(euthyroid subjects on replacement therapy will be included if the dosage of thyroxine is 
stable for  at least six weeks prior to Screening).  
3. Clinical diagnosis of type 1 diabetes.  
4. Fasting serum  glucose >300 mg/dL at Screening; a single repeat test is allowable.  
5. Evidence of unawareness of hypoglycemia, a documented plasma glucose ≤50  mg/dL in 
the absence of symptoms of hypoglycemia at Screening.  
6. Presence of any clinically significant condition (in the opi[INVESTIGATOR_689]) that 
might interfere with the evaluation of study medication, such as significant renal, hepatic, 
gastrointestinal (GI), cardiov ascular (CV), immune disease, blood dyscrasias or any 
disorders causing hemolysis or unstable red blood cells, or clinically important 
hematological disorders (i.e. aplastic anemia, myeloproliferative or myelodysplastic 
syndromes, thrombocytopenia ) at Scre ening.  
7. Presence or history of cancer within the past [ADDRESS_427213] with a history of malignancy >[ADDRESS_427214] with a history of melanoma, leukemia, lymphoma,  or renal carcinoma is 
excluded.  
8. Laboratory abnormalities at Screening including:  
a) C-peptide < 1.0 ng/mL  
b) Positive pregnancy test in females of c hildbearing potential (at Screening and 
Visit 2/Period s 1-3/Day 1)  
c) Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or 
>1.5X the upper limit of normal  
d) Elevated liver enzymes (alanine transaminase (ALT), alanine aminotransferase 
(AST) , alkaline phosphatase) >2X the upper limit of normal.  
e) Very high triglyceride levels (>600 mg/dL); a single repeat test is allowable.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 34 
CONFIDENTIAL  f) Any relevant abnormality that would interfere  with the efficacy or the safety 
assessments during study treatment  administration.  
9. Positive history of active liver disease (other than non -alcoholic hepatic steatosis), 
including chronic hepatitis B or C , primary biliary cirrhosis, or active symptomatic 
gallbladder disease.  
10. Positive history of HIV.  
11. Use of the following medications:  
a) History of use of insulin for more than 1 week within 6 months prior to and none 
within 6 weeks prior to Visit 2/Period 1/Day 1.  
b) History of use of aprotinin at any time prior to Screening (e.g., Trasylol, any type 
or dose) . 
c) Administration of t hyroid preparations or thyroxine (except in subjects on stable 
replacement therapy) within 6 weeks prior to Screening.  
d) Administration of systemic long -acting corticosteroids within two months or 
prolonged use (more than one week) of other systemic corticos teroids or inhaled 
corticosteroids (if daily dosage is > 1,000 μg equivalent beclomethasone) within 
30 days prior to Screening.  Intra -articular and/or topi[INVESTIGATOR_344248].  
e) Use of medications known to modify glucose metabolis m or to decrease the 
ability to recover from hypoglycemia such as oral, parenteral, and inhaled  steroids 
(as discussed above) , and immunosuppressive or immunomodulating agents.  
12. Known allergy to soy or aprotinin.  
13. Subject is on a weight loss program and is n ot in the maintenance phase, or subject has 
started weight loss medication (e.g., orlistat or liraglutide), within [ADDRESS_427215] has a  Screening systolic blood pressure ≥165 mmHg or diastolic blood pressure 
≥[ADDRESS_427216] is a user of recreational or illicit drugs or has had a recent history (within 1 year 
of Screening) of drug  or alcohol abuse or dependence. (Note: Alcohol abuse includes 
heavy alcohol intake as defined by >3  drinks per day or >14 drinks per week, or binge 
drinking) at Screening.  
17. Any clinically significant ECG  abnormality at Screening or cardiovascular disease. 
Clinically significant cardiovascular disease will include:  
a) History of stroke, transient ischemic attack, or myocardial infarction within 6 
months prior to Screening,  
b) History of or currently have [LOCATION_001] Heart Associate Class II -IV heart failure 
prior t o Screening, or  
18. One or more contraindications to metformin.  
19. History of gastrointestinal disorders (e.g. hypochlorhydria) with the potential to interfere 
with drug absorption.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 35 
CONFIDENTIAL  20. At the Principal Investigator’s discretion, any condition or other factor that i s deemed 
unsuitable for subject enrollment into the study.  
4.[ADDRESS_427217]’s participation in the study:  
1. Subject experiences an AE that in the judgement of the Investigator poses a significant risk 
to the subject for continued participation in the study .  
2. Subject  uses a prohibited med ication (listed in Section 5.7 ) that in the judgment of the 
Investigator poses a significant risk to the subject for continued participation in the study 
or that will interfere with the interpretation of the results of the study.  
3. Subject becomes pregnant.  
4. Significant protocol violation or noncompliance on the part of the subject or the 
Investigator.   
5. Intercurrent illness that requires treatment that is not consistent with the protocol 
requirements, or intercurrent illness or the associ ated treatment that in the judgment of the 
Investigator poses a significant risk to the subject for continued participation in the study.   
6. Subject wishes to withdraw for any reason.  
7. Sponsor elects to end the study, or the Investigational Site elects to en d the study at their 
site.  
8. Any other reason  that in the judgment of the Investigator  poses unacceptable risk to the 
subject . 
 
Reasons for study drug discontinuation may include the following:  
1. Pregnancy  
2. Adverse event  
3. Epi[INVESTIGATOR_344249] 7.3.1.  
4. Patient meets one of the exclusion criteria during the study  
5. Any clinically significant change in the patient’s medical condition  
 
The occurrence of severe hypoglycemia (as defined in Section  7.3.1 ) in two patients during the 
double -blind tr eatment period will lead to unblinding of the treatment in those two patients.  
Patients who withdraw from the study prior to treatment may be replaced. Patients who are 
withdrawn and have received at least one treatment will not be replaced. Patients who 
discontinue study drug treatment will not be replaced.  
Except in cases of emergency, the Investigator should consult with the Sponsor and the  Medical 
Monitor  before removing the subject from the study.  In some circumstances it may be necessary 
to temporarily interrupt treatment as a result of AEs that may have an unclear relationship to 
study  treatment .  The Investigator should obtain approval from the Sponso r and Medical Monitor  
before restarting study treatment s that were temporarily discontinued for an AE. 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427218] will not be obliged to give his/her reason for withdrawing prematurely, the 
Investigator will make  a reasonable effort to obtain the reason while fully respecting the 
subject’s rights.   
All sub jects who are randomized and treated (i.e. , receive d any amount of study treatment ) will 
be included in the safety analyses.  Thus, every effort will be  made to contact a ny subject who 
fails to attend any follow -up appointments/contacts, in order to ensure  that he/she is in 
satisfactory health.  If a subject withdraw s from the study as a result of meeting discontinuation 
criteria  after the start of study treatment  administration, reasonable efforts should be made to 
have the subject return for the  early wit hdrawal  evaluations (Section 3.5).  Any subject 
withdrawn due to a suspected study treatment  -related AE should be followed until resolution or 
stabilization of the event.  
If a subject becomes pregnant, study treatment  will be discontinued immediately, and the subject 
will be referred to an obstetrician/gynecologist experienced in reproductive toxicity for further 
evaluation and counseling.  The subject will be followed until delivery or other termination of 
pregnancy f or outcome.  
Subjects may choose to withdraw authorization to use and disclose their PHI as defined by [CONTACT_248453].  Such withdrawal of authorization must be made to the Investigator in writing.  Any PHI 
collected by [CONTACT_344261].  
Randomized subjects who are discontinued from this study for any reason will not be replaced.   
The Sponsor has the right to terminate this study, and the Investigator/Investigational Site has the 
right t o close the site, at any time, although this should occur only after consultation between 
involved parties.   The Investigator will notify the IRB in writing of a premature termination of a 
study or closure of Investigational Site , and will send a copy of t he notification to the Sponsor.    
Events that may trigger premature termination of a study or closure of an Investigational Site 
include, but are not limited to , a new toxicity finding , a request to discontinue the trial from a 
regulatory authority, non-compliance with the protocol , GCP violations, slow recruitment /low 
enrollment , or chang e in development plans for the study treatment . 
If either of the criteria listed below is met , enrollment of new subjects and dosing of ongoing 
subjects will be temporaril y stopped.  T he Investigator , Sponsor,  and the Medical Monitor  will 
discuss whether a lower dose or any additional treatment guidelines should be implemented, or if 
the trial should be permanently stopped.  Any proposed changes to the protocol to address such 
findings will be submitted for review and approval by [CONTACT_344262] -starting the 
trial. 
1. A death within 30 days after study treatment  administration where there is a reasonable 
possibility that the drug caused the event;  
2. Two Grade 4 AEs w here there is a reasonable possibility that the study treatment  caused 
the events.  
 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 37 
CONFIDENTIAL  5 STUDY TREATMENT  
5.1 Description of Investigational Drug  
Active:  
Code name: [CONTACT_248483] -0801  
Dosage form: 2 soft gel c apsule s per dose  
Strength: 230 IU insulin (8  mg insulin)  per capsu le 
Description: API (recombinant human insulin USP), in Oramed’s proprietary formulation 
[aprotinin, SBTI, disod ium EDTA, fish oil, and TWEEN 80 ] in capsules.  
Placebo control:  
Fish oil in capsules, identical in appearance to ORMD -0801  
Note:  [ADDRESS_427219] will remove the 
capsules from the bottle  before providing  the capsules  to the Investigational Site personnel . 
Shipments of placebo capsules for the run -in period will be clearly l abeled to indicate they 
should be used during this patient -blinded stage of the study.  Shipments of study medication for 
the double -blinded treatment period will be received in blinded packages so that the Investigator, 
staff, and patients will be blinded  to the treatment. Study medication will be dispensed to the site 
with instructions for when treatment can be administered and with a diary for recording 
administration of study medication. Medication containers and any unused capsules will be 
retained at the study site after the treatment phase of the trial is complete.  
The treatment packages  will be labeled with the following information:  
 Study number  
 Patient ID  
 Kit No./Bottle ID  
 Dosage Form /Content  
 Directions for use, including route of administration  
 Number of capsules in package  
 Storage conditions  
 Instructions to “keep out of reach of children”  
 Caution: New Drug  – Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use.   
 Name [CONTACT_790]   
A separate label with the identical information will be provided with the label on the package  for 
drug accountability purposes .  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427220] be kept in an appropriate, secure area  to prevent unauthorized access .  
The study treatment  is to be shipped under ambient conditions and stored in the original 
packaging at controlled ro om temperature ( 62 to 77°F; 17 to 25°C).  Excursions between 59 to 
86ºF (15 to 30ºC) will be permitted.   Excessive humidity should be avoided.   Storage conditions 
will be monitored and appropriate monitori ng logs maintained as source data.  Deviations from 
the established temperature, as well as the occurrence of excessive humidity, should be 
documented, and the Sponsor should be notified.  
Study treatment  should be handled and disposed of using proper proc edures as defined by 
[CONTACT_344263] (SOPs) for Investigational Drugs . 
5.[ADDRESS_427221] crossover  study .  Approximately 30 
eligible s ubjects will be randomized to placebo and 2 of the 3 possible dose groups: O RMD -
0801 460 IU qd  (in the evening), ORMD -0801 460 IU bid  (in the morning and evening) and 
ORMD -0801 460 IU tid  (morning, afternoon , and evening).  
In order to estimate the morning, afternoon , and evening PD ef fect, each subject will have one 
period in which the PD blood samples are drawn  in the morning, one period in which the PD 
blood samples are drawn  in the afternoon and one period in which the PD blood samples are 
drawn  in the evening. When the subject is o n active therapy, the PD blood samples will be drawn  
after an active therapy dose  (not after the placebo dummy) . Thus , if the subject is taking  ORMD -
[ADDRESS_427222] is taking  ORMD -0801 460 IU tid or  placebo, the PD blood samples will be drawn  in the 
morning, afternoon , or evening.  
Integrium, LLC will generate and implement the randomiz ation procedures for this trial.  A 
computer -generated randomization schedule will be used for assigning treatment (active or 
placebo).  The Investigational Site pharmacist will follow this randomization schedule to 
dispen se the appropriate study treatment . 
5.3 Study Treatment  Administration  
5.3.1  Study Treatment Period s  
In order to achieve the desired 460 IU, 2 capsules will be administered per dose.  Accordingly, 
subjects who are randomized to placebo will also receive 2 identical placebo capsules per dose.  
[IP_ADDRESS]  Singl e-Blind Placebo Administration  
Placebo will be administered during Visit [ADDRESS_427223] 45 
minutes before lunch on Day 2.  Subjects will be provided with an  evening dose of placebo at 
approximately 10 pm (± 60 minutes) on Day 2.  On Days 3 and 9, subjects will receive a dose of 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 39 
CONFIDENTIAL  single -blind placebo at approximately 7am (± 60 minutes),  approximately 1pm (± 60 minutes), 
and before bed at approximately 10 pm (± 60 minutes) . 
[IP_ADDRESS]  Double -Blind Trea tment Administration  
Study treatment (active or placebo) will be administered during Visit [ADDRESS_427224] indicate a blood glucose of ≥70 mg/ dL. On all days , subjects will receive 
a dose of study treatment or placebo at approximately 7am (± 60 minutes), approximately 1pm 
(± 60 minutes), and a dose before bed at approximately 10 pm (± 60 minutes) .   
Subjects may be randomized to rec eive ORMD -0801 qd, bid, or tid:  
 Subjects receiving ORMD -0801 qd will receive their dose at approximately 10pm (± 60 
minutes) , while receiving  identical  placebo at approximately 7am (± 60 minutes) and at 
approximately 1pm (± 60 minutes) .   
 Subjects receiving ORMD -0801 b id will receive their doses at approximately 7am (± 30 
minutes) and  before bed at approximately 10pm (± 60 minutes) , while receiving placebo 
at approximately 1pm (± 60 minutes) .   
 Subjects receiving ORMD -0801 tid will receive their doses at approximately 7 am (±  60 
minutes),  at approximately 1pm (± 6 0 minutes),  and before bed at approximately 10pm 
(± 60 minutes).  
5.4 Dose Modifications  
This study does not include any planned dose modifications.  Subjects will be administere d study 
treatment  orally at the a ssigned (randomized) dose level  unless discontinuation criteria as defined 
in Section  4.[ADDRESS_427225] Compliance  
5.5.1  Study Treatment Period s 1 and 2  
Four doses of placebo  (8 capsules)  will be dispensed to subjects for Day [ADDRESS_427226] the single -blind nature of this 
treatment.  
All doses of study treatment  will be administered in the CRU.  Oral dosing c ompliance will be  
ascertained by [CONTACT_344264]  (mouth check) following dosing.    
5.[ADDRESS_427227] will be provided to the Sponsor.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427228]’s 
source documents and CRF.  
5.7 Concomitant Medications  and Supplements  
All medications and supplements  (other than study treatment ) taken by [CONTACT_248463] 
2/Day 1 through the Follow -up Visit 3 will be considered “concomitant ” medications  and 
supplements .  Medications and supplements taken prior to Visit 2 that are no longer being taken 
at the time of Visit 2/Day 1 will be con sidered “prior” medications and supplements.  
All prior medications and supplements taken within [ADDRESS_427229]’s source 
document ation  and in the CRF.  
The use of concomitant medications and supplements should be kept at a minimum, if possible.  
Any medications  and supplements  needed for the welfare of a subject and that in the judgment of 
the Investigator will not pose a significant risk to the sub ject for continued participation in the 
study or that will not interfere with the interpretation of the results of this study  may be given to 
the subject .  If a subject requires the use of any of the  prohibited medication s and supplements  
listed below , the Investigator will contact [CONTACT_344265]’s continued participation in the study.  In the event of an emergency, subjects will be 
treated at the discretion of the Investigator according to acceptable community standards of 
medical care.   
The following are prohibited medica tions:  
1. Any I nvestigational Drug other than ORMD -0801 (or placebo)  within 30 d ays prior to Visit 
2/Day 1 through the Follow -Up Visit 3; 
2. Any anti -diabetic drugs (except for those allowable by [CONTACT_113994])  including 
insulin,  GLP-1 analogue, α -gluco sidase inhibitors, glinides, and pramlintide ; 
3. Aprotinin (e.g., Trasylol) ; 
4. Thyroid preparations or thyroxine (except in subjects  on stable replacement therapy);  
5. Systemic long -acting corticosteroids or other systemic corticosteroids or inhaled 
corticosteroids (if daily dosage is > 1,000 μg equivalent beclomethasone) . Intra -articular 
and/or topi[INVESTIGATOR_344250].  
6. Medications known to modify glucose metabolism or to decrease the ability to recover 
from hypoglycemia su ch as oral, par enteral, and inhaled steroids,  and 
immunosuppressive or immunomod ulating agents.   
If the subject  initiates prohibited drug therapy, or if the Investigator determines that use of a 
prohibited therapy is in the best interest of the patient’s health and well -being, the Investigator 
and sponsor will jointly decide to continue or discontinue the subject . 
5.[ADDRESS_427230] 8 hours prior to the clinical safety labs at Screening . 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427231] 45 minutes or more prior to scheduled ORMD -
0801 (or placebo)  dosing as described in the st udy design.  All s ubjects will be provided with a 
standardized diabetic breakfast on Day 1, then continuing  from  dinner o n Day [ADDRESS_427232] and lunch, 
between lunch and dinner, and between dinner and bedtime.  
Excessive caffeine use (i.e., more than five cups of caffeinated beverages per day) will not be 
allowed from Screening through th e Follow -Up Visit  3.  Excessive alcohol use or binge drinking 
will be discouraged during the study, and alcohol will be p rohibited 72 hours prior to  admission  
to the CRU ( Visit 2/Period 1, 2, and 3/ Day 1) and throughout the domiciled period  (i.e., through 
the morning assessments on Day 10). 
Subjects will also be asked to refrain from any unusual or unaccustomed vigorous exercise 
during the course of the study.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 42 
CONFIDENTIAL  6 STUDY PROCEDURES AND  ASSESSMENTS  
6.1 Informed Consent  
According to the I CH guideline for GCP (E6)  and all institutional local, state, and federal laws , 
the Investi gator will obtain and document informed consent  for each subject screened for this 
study.  All subjects will be informed in writing of the nature of the protocol and Investigational 
Drug , its po ssible hazards, and their right to withdraw at any time, and will sign a form  (ICF)  
indicating their consent to participate in the study prior to the initiation of study procedures.  The 
subject’s medical record should contain written documentation indicat ing that info rmed consent 
was obtained.  The ICF must be reviewed and approved by [CONTACT_737]’s designated IRB and 
by [CONTACT_248433].  designee prior to its use .  Refer to Section 11.1.[ADDRESS_427233] 
wearing no shoes.  
6.3.2  Vital Signs  
Vital sig ns (inclu ding seated SBP/DBP, and heart rate ) will be recorded at all visits as described 
in Table 1 . Temperature will be recorded at Visit 2/Day [ADDRESS_427234] 5 minutes  in a quiet envi ronment and prior to any 
blood draw that occurs at the same time point.  During Treatment Periods 1, 2, and 3,  vital signs 
will be measured  on Day 1, at admission on Day 2, immediately prior to morning dosing on 
Days 3 -9, and on the morning of Day 10 prior to discharge.   The recorded seated SBP/DBP value 
will be the mean of two measurements taken 2 minutes apart and always using the non-dominant 
arm. 
6.3.3  Physical Examination  
A physical examination will be p erformed at Screening and at Follow -Up Visit 3, or in case of 
Early Withdrawal.  The physical examination will include the following organ or body system 
assessments:  skin; head, eyes, ears, nose, and throat; thyroid; lungs; cardiovascular; abdomen 
(liver, spleen); lymph nodes; and extremities , as well as an abbreviated neurological 
examination . 
6.3.[ADDRESS_427235] 5 minutes in the supi[INVESTIGATOR_33197] a quiet environment.  ECGs 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 43 
CONFIDENTIAL  will be read for QT and QTc  (Federicia’s)  intervals and clinically significant abnormalities.  At 
the Investigator’s discretion, an additional ECG may be performed at the end of treatment; 
however, it will be recorded in source documents as an unscheduled assessment.  
6.3.[ADDRESS_427236] procedures.  A local laboratory will perform all clinical laboratory tests . 
In the event of abnormal clinical laboratory values, the Investigator  will make a judgment 
whether or not the abnormality is clinically significant.  
[IP_ADDRESS]  Clinical Safety Labs  
The clinical safety labs will include the following hematology, serum chemistry, and u rinalysis 
tests:  
Hematology  
 Hematocrit  
 Hemoglobin  
 Mean corpuscular hemoglobin  
 Mean corpuscular hemoglobin concentration  
 Mean corpuscular volume  
 Platelet count  
 Red blood cell distribution width  
 Red blood cell count  
 White blood cell count  with differential  
Serum Chemistry  
 Sodium  
 Potassium  
 Chloride  
 Bicarbonate  
 Alanine aminotransferase (ALT)  
 Aspartate aminotransferase (AST)  
 Gamma -glutamyltransferase (GGT)  
 Total bilirubin  
 Alkaline phosphatase  
 Albumin  
 Total Protein  
 Blood urea nitrogen (BUN)  
 Creatinine  
 Uric acid 
 Glucose  
 Calcium  
 Phosphorus  
 Total cholesterol  
 Triglycerides  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 44 
CONFIDENTIAL  Urinalysis  
 Appearance (color and character ) 
 Bilirubin  
 Urobilinogen  
 Protein  
 Glucose  
 Ketones  
 Leukocyte esterase  
 Urine  blood  
 Nitrite  
 pH 
 Specific gravity  
 
[IP_ADDRESS]  Pregnancy Test  
A serum pregnancy test will be performed for WCBP at Screening. A urine  pregnancy test will 
be performed for WCBP at treatment Periods 1, 2, and 3  (Day 2). 
FSH testing to confirm menopause should be done for women who have had more than [ADDRESS_427237] menstrual cycle, who are younger than 55 years old, and who are not 
surgically menopausal.  
 
[IP_ADDRESS]  Additional Screening Bloodwork  
In addition t o the blood tests listed above,  HbA 1c, C-peptide, and thyroid stimulating hormone 
(TSH) will be measured at Scre ening.   
[IP_ADDRESS]  Drugs of Abuse  and Breathalyzer  
Drugs of abuse urine screens will be completed at Screening and at Visit 2/Day 2 (all three 
treatment Periods) according to the laboratory manual provided by [CONTACT_344266], barbiturates, cocaine metabolites, opi[INVESTIGATOR_858], benzodiazepi[INVESTIGATOR_344251].  A breathalyzer test will also be performed at Screening and at Visit 2/Day 2 
(all three treatment Periods) . 
6.4 Efficacy Assessments  
6.4.1  Continuous Glucose Monitors (CGM)  
A continuous glucose monitor (CGM) will be used to monitor patient glucose levels (including 
post-prandial) during Visit 2, Periods 1, 2, and [ADDRESS_427238]  data until the morning of 
Day 10. Staff will be advised regarding appropriate procedures in the event of noctu rnal 
hypoglycemia.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 45 
CONFIDENTIAL  6.5 Pharmacokinetic/ Pharmacodynamic  Assessments  
Blood samples for PK/PD  analysis  of absorbed insulin based on C -peptide correction of total 
insulin levels will be collected during Visit  2, Periods 1, 2, and 3, on Day 3 and Day 8 . An 
indwelli ng venous catheter may be inserted for the collection of blood samples if deemed 
necessary. One 4.5 mL  sample  of total whole blood will be collected for each blood draw.  
 
On Day 3, b lood samples will be collected at the following nominal time points  relative to the 
scheduled  (per randomization scheme) dose o f placebo : predose ( 45 to 5 mins prior to dosing)  
and every 30 minutes (± 5 minutes) postdose until 5 hours  has elapsed . On Day 8, b lood samples 
will be collected at the following nominal time poi nts relative to the scheduled (per 
randomization scheme)  dose of study treatment ( active or placebo): predose ( 45 to 5 mins prior 
to dosing)  and every 30 minutes (± 5 minutes) postdose until 5 hours  has elapsed .  The total 
volume collected from each subjec t for PK/PD samples will be approximately [ADDRESS_427239] taken within 30  days prior to Visit 
2/Day [ADDRESS_427240]’s medical record and the CRF.   
All medications and supplements  (other than study treatment ) taken by [CONTACT_248458] 
2/Day 1 through Follow -Up Visit 3 assessment s will be considered “concomitant ” medications  
and supplements .  Medications and supplements taken prior to Visit 2/Day 1  that are no longer 
being taken at Visit 2/Day 1  will be considered “prior” medications and supplements.  
Medications and supplements should be recorded according to the generic name [CONTACT_248484].   
The use of c oncomitant medications and supplements should be limited to those that are 
medically necessary .  Any medication  or supplement  used should have an indication recorded , 
and for concomitant medications and supplements, this indication must be represented as either  
for the treatment of an AE , for the management of a pre -existing condition, or for proph ylaxis.   
Dosage increases for any concomitant medication  or supplement  should be noted and the reason 
for the dosage increase recorded as an  AE (assumes worsening condition).   The side effects of 
concomitant medications will be recorded as AEs.  
Any subjec t whose condition becomes disqualifying  during the course of the study may be 
treated for that condition .  If the condition  is suspected during Screening , the subject should not 
be enrolled.  Treatment of the condition should be instituted according to the 
Investigator’s/attending physician's judgment.   
Medications that have no treatment intent but rather are part of supportive routine care such as 
local anesthetics, intravenous solutions to maintain fluid balance and ke ep access open, 
medications used for prophylaxis, and narcotics for postsurgical pain must also be recorded in 
the subject’s medical record and CRF. 
 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 46 
CONFIDENTIAL  7 ADVERSE EVENTS AND S AFETY REPORTING  
7.1 Safety and Tolerability Assessments  
Safety and tolerability will be as sessed on an ongoing basis by [CONTACT_1125], physical 
examinations, 12 -lead ECGs, vital signs (including weig ht, seated SBP/DBP, heart rate , and 
temperature), and clinical safety labs (hematology, serum chemistry, and urinalysis).  
7.2 Definition of Ad verse Event  
An AE is defined in 21 CFR 312.32(a)  as follows:  
Any untoward medical occurrence associated with the use of a drug in humans, whether or 
not considered drug related.  
An AE (also referred to as an adverse experience) can be any unfavorable and unintended sign 
(e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of 
a drug, and does not imply any judgment about causality .  An AE can arise with any use of the 
drug (e.g., off -label use, use in combination wi th another drug) and with any route of 
administration, formulation, or dose, including an overdose.  
AEs will be regarded as “pretreatment”  if they occur during the placebo washout period or 
placebo run -in period.  TEAEs are defined as any AE that starts  or increases in severity after the 
first randomized dose of study treatment  (active or placebo)  on Day 4 .  
7.3 Definition of Serious Adverse Event  
A SAE is defined in 21 CFR 312.32(a) as follows : 
An AE is considered “serious” if, in the view of either the Inves tigator or Sponsor, it results 
in any of the following outcomes : 
 Death; 
 Life-threatening  AE; 
 Inpatient  hospi[INVESTIGATOR_1081] ; 
 Persistent  or significant  incapacity  or substantial disruption of the ability to conduct 
normal life functions;  
 Congenital anomaly/birth defect.  
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_708], based upon a ppropriate medical judgment, they 
may jeopardize the patient or subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition.  Examples of such medical events include allergic 
bronchospasm requiring inte nsive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 47 
CONFIDENTIAL  An AE is considered “life -threatening” if, in the view of either the Inve stigator or Sponsor, its 
occurrence places the patient or subject at immediate risk of death.  It does not include an AE 
that, had it occurred in a more severe form, might have caused death.  
7.3.1  Adverse Events of Hypoglycemia  
The CTCAE (version 4.0) definition  for mild, moderate, and severe hypoglycemia based on blood 
glucose will be used, as shown below:  
Mild: from 55 to <70 mg/dL (3.0 to < 3.8 mmol/L)  
Moderate: from 40 to < 55 mg/dL (2.2 to < 3.0 mmol/L)  
Severe: from 30 to < 40 mg/dL (1.7 to < 2.2 mmol/L)  
Life Threatening: < 30 mg/dL (< 1.7 mmol/L)  
7.[ADDRESS_427241]'s source documentation and in the CRF.  
Subjects will be instructed to report al l AEs experienced during the study , and subjects will be 
assessed for the occurrence of AEs  throughout the study .  In order to avoid bias in eliciting AEs, 
subjects will be asked general, non -leading questions such as "How are you feeling?"    
All AEs, incl uding pretreatment and TEAEs,  reported by [CONTACT_423], observed or otherwise 
identified by [CONTACT_737], or other Investigational Site  personnel will be documented.    
Medical conditions existing at Screening should be recorded as medical history.  New or 
worsening pre -existing m edical conditions or diseases are considered AEs if they arise or worsen 
after the Screening visit, and should be recorded as AEs . 
Surgical procedures themselves are not AEs; they are therapeutic measures for conditions that 
require surgery.  The condition for which the surgery is required is  an AE if it occurs or is 
detected following the first dose of Study treatment  through the Fol low-Up Visit .  Conditions 
leading to planned surgical procedures are not AEs if the condition(s) was (were) known before 
study treatment .  In the latter case, the condition should be reported as medical history.  
7.4.[ADDRESS_427242]’s source documentation and on the AE page of the CRF .  Copi[INVESTIGATOR_344252] 21 CFR 312.32 (see Section 7 .4.2 for f urther detail) and regular 
regulatory reporting requirements under 21 CFR 312.33 .  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 48 
CONFIDENTIAL  For each AE, the following information will be entered in the CRF:  
 Medical diagnosis of the event in standard medical terminology (if a medical diagnosis 
cannot be determine d, a description of each sign or symptom characterizing the event) ; 
 Date of onset of any new AE or worsening of a previously observed AE.  For the days 
when the subject is housed in the CRU (Day 1 -2), the time (based on a 24 -hour clock) of 
onset should be recorded if available;  
 Date of resolution of the event (or confirmation ongoing).  For the days when the subject 
is housed in the CRU (Day 1 -2), the time (based on a 24 -hour clock) of resolution should 
be recorded if available;  
 Whether the event is serious  (per definition in Section 7 .3), and if so, the reason it is 
considered serious;  
 Severity  of AE (per definition in Section 7 .6); 
 Assessment of the at tributability of the AE to the s tudy treatment  [per definition in 
Section 7 .5];  
 Whether the event is expe cted (per definition in Section 7 .7); 
 Action taken in treating the AE  (including concomitant medicat ions or therapi[INVESTIGATOR_124888]) and/or change in t he study treatment  administration or dose (including 
whether the study treatment  was temporarily interrupted or discontinued) ; 
 Outcome of AE (per definition in Section 7 .8).   
7.4.[ADDRESS_427243] 
information for the Medical Monitor is provided below.  
Medical Monitor:   
Carmen Marga ritescu, MD  
Safety Office, Integrium, LLC  
Office: 7 14-210-6665  
Cellular: 714 -328-7083  
Email: [EMAIL_6671]  
 
SAE Forms will be provided by [CONTACT_344267].  If all information is 
not known at the time of initial reporting, an initial report should still be made.  In the event there 
is a question as to whether the experience is serious, the i nformation should be forwarded to the 
Medical Monitor for review.  The Investigator is responsible for following up on completion of 
the SAE Form.  The Investigator will submit substantiating data in hard copy form, such as 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427244] reports and prog ress notes, to the Medical Monitor.  In the case of fatality, 
autopsy reports will be furnished to the Medical Monitor as soon as available.   If the Medical 
Monitor is informed of a SAE via a telephone call, preliminary information will be obtained, and 
the study site will be instructed to fax an SAE Form.  
In the event of a medical emergency or an SAE that is unex pected (as defined in Section 7 .7) and 
possibly related to the study treatment (s) (i.e., an adverse reaction or suspected adverse reaction 
as def ined in Section  7.5), the blind will be broken for the subject that experiences the event. An 
emergency code break envelope for each subject will be provided to the Investigational Site and 
also to the Medical Monitor.  In the event that the Investigationa l Site personnel need to unblind 
the study treatment and cannot access the relevant code break envelope at the site, they can 
contact [CONTACT_1689].  
The initial SAE Form and any subsequent follow -up SAE Forms submitted to provide more 
accurate, corre cted, or new information must be signed by [CONTACT_737].  The Investigator and 
Investigational Site Personnel must make every reasonable effort to obtain, from other 
institutions if necessary, all supporting medical case records as needed to comply wit h expedited 
Investigational New Drug application (IND) safety reporting requirements.   
If the SAE involves expedited IND safety reporting (as determined by [CONTACT_16015]), 
all supporting medical records must be submitted to the Sponsor or design ee within [ADDRESS_427245] also promptly inform the governing IRB of the SAE  in accordance with  
the governing IRB’s requirements .  Any SAE that is determined by [CONTACT_344268] (as defined in 21 CFR 312.32) will be reported to FDA by 
[CONTACT_344269].  All IND Safety Reports will also be 
promptly provided to the Investigator for sub mission to his/her IRB.  Similarly, any SAE that is 
determined by [CONTACT_344270], and wi ll be provided to the Investigator for submission to his/her IRB.  
The Investigator , Medical Monitor , and Sponsor  will review each SAE report and evaluate the 
relationship of the adverse experience to study treatment  and to underlying disease.  Based on 
this assessment, a decision will be made concerning the need for further action.  The primary 
consideration governing further action is whether new findings affect the safety of subjects 
participating in the clinical trial.  If the discovery of a new adverse experience related to the 
study treatment  raises concern over the safety of continued administration o f study treatment , the 
Sponsor will take immediate steps to notify the regulatory authorities.  
Further action that may be required includes the following:  
1. Alteration of existing research by [CONTACT_124938];  
2. Discontinuation or suspension of the study;  
3. Alteration of the informed consent process by [CONTACT_124939];  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427246] or partner s hould be followed by [CONTACT_42498]. 
If the pregnancy ends for any reason before the anticipated date, the Investigator should notify 
the Sponsor. At the completion of the pregnancy, the Investigator will document the ou tcome of 
the pregnancy. If the outcome of the pregnancy meets the criteria for immediate classification as 
an SAE (i.e., postpartum complication, spontaneous abortion, stillbirth, neonatal death, or 
congenital anomaly), the Investigator should follow the p rocedures for reporting an SAE.  
7.5 Causality Assessment of Adverse Events  
For all AEs, the Principal Investigator [INVESTIGATOR_344253]  (active or placebo) .  The causality assessment must be recorded in the subject’s 
source documents and on the AE CRF.  Causal relationship will be classified acco rding to the 
following criteria:  
1. Unrelated : The event is clearly  due to causes  other  than the active  study  drug.  
2. Unlikely : The event is doubtfully  related  to active  study  drug.   The event  was most likely  
related  to other  factors  such as the patient’s  clinical  state,  concomitant  drugs  or other 
therapeutic  interventions.  
3. Possible : The event  follows a  reasonable temporal  sequence  from  the time of active study  
drug administration,  but could  have been produced  by [CONTACT_344271]’s  
clinical  state,  therapeutic interventions  or concomitant  drugs.  
4. Probable : The event  follows a  reasonable temporal  sequence from  the time of active study  
drug administration,  and follows  a known response pattern  to the  drug.  The toxicity  cannot  
be reasonably  explained  by [CONTACT_344271]’s  clinical  state,  therapeutic 
interventions  or concomitant  drugs.  
5. Definite : The event  follows a  reasonable te mporal  sequence  from  the time of active study  
drug administration,  follows  a known  response pattern  to the  drug,  cannot  be reasonably  
explained  by [CONTACT_344271]’s  condition,  concomitant  drugs  or therapeutic 
interventions,  AND either occurs  immediately  following  active  study  drug administration,  
improves on stoppi[INVESTIGATOR_266033],  or reappears  on re-exposure.  
 
7.5.1  Potential Adverse Events Associated with ORMD -0801  
Hypoglycemia and associated symptoms (e.g., weakness, dizziness, shakiness,  increased 
sweating, palpi[INVESTIGATOR_814], or confusion), have been associated with insulin administration, including 
ORMD -0801. Animal reproductive studies have not been conducted with ORMD -0801. It is not 
known whether ORMD -[ADDRESS_427247] is excreted in human milk. Pregnant or breastfeeding 
women are excluded from this study.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427248] CAE, and as summarized in the table below.  
General Guidelines for Severity Assessment of Adverse Events  
Grade 1 :  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated.  
Grade 2 :  Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental activities of daily living (ADL) [preparing meals, shoppi[INVESTIGATOR_16208], using the telephone, managing money, etc.].  
Grade 3 :  Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self -care 
ADL (bathing, dressing and undressing, feeding self, using the toilet, taking medications, 
and not bedridden).  
Grade 4 :  Life -threatening consequences; urgent intervention indicated.  
Grade 5 : Death related to AE.  
 
Note the distinction between the severity and the seriousness of an AE.  A severe AE is not 
necessarily a SAE.  For example, a headache may be severe (interferes sig nificantly with 
patient's usual function) but would not be classified as serious unless it met one of the criteria for 
SAEs, listed above in Section 7 .3. 
7.7 Expectedness of Adverse Event  
An unexpected AE is defined in 21 CFR 312.32(a)  as follows : 
An AE is con sidered “unexpected” if it is not listed in the IB or is not listed at the specificity 
or severity that has been observed; or, if an IB is not required or available, is not consistent 
with the risk information described in the general investigational plan or elsewhere in the 
current application, as amended.  
7.8 Assessment of Adverse Event Outcome  
Outcome of AEs will be defined according to ICH Topic E2B, ICH Guideline.  
 Recovered/Resolved:   The subject has recovered fully from the AE without any 
remaining effects or impairment.  
 Recovered/Resolved with Sequelae :  The subject has recovered, but with an after effect 
possibly due to disease or treatment.  
 Not Recovered/Not Resolved:   The conditi on is still present.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 52 
CONFIDENTIAL   Fatal :  Fatal should only be used when death is possibly related to the AE.  
 Unknown :  The primary outcome is not known at the time of the final assessment.  If an 
outcome for an AE is not available at the time of the initial report, follow -up will proceed 
until an outcome is known  or followed up to the Final Study Visit .  Any subject with a 
possible study treatment -related AE at the Final Study Visit will be followed until 
resolution or stabilization of the event.  Further, any SAE, w hether or not related to Study 
treatment  (active or placebo), that occurs within [ADDRESS_427249] dose of Study 
treatment  will be followed until resolution or stabilization of the event.  
7.9 Clinical Findings  
Any significant clinical findings at the Follow -Up Visit will be followed until the condition 
returns to pre -study status, stabilize s, or can be explained as not being study treatment  related.  If 
the clinical finding is reported as an AE (per the criteria outlined in Section  10.2) , the follow -up 
procedures for AEs defined above will apply.  
 
8 STATISTICAL METHODS  
This section describes the statistical methods to be used for the analysis and reporting of data 
collected under Protocol No. ORA -D-012.  Additional details will be provided in the statisti cal 
analysis plan . 
8.1 Sample Size  
A total of 30 subjects will be randomized  to receive  either placebo, ORMD -0801 460 IU qd, 
ORMD -0801 460 IU bid, or ORMD -0801 460 IU tid during each  treatment period.    
Safety will be a secondary endpoint for this trial and will be assessed primarily based on AEs.  
Secondary safety assessments will include physical examination , 12-lead ECG, vital signs 
(including weight, seated SBP/DBP, heart  rate, and temperature),  and clinical safety labs 
(hemato logy, serum chemistry, and urinalysis) . 
This study is not powered for statistical significance .   
8.2 Pharmacokinetic/ Pharmacodynamic  Evaluation  
The PK/PD analysis will be conducted using model -independent methods and will be based o n 
plasma concentrations of insulin and C -peptide . 
Individua l plasma concentrations of insulin and C -peptide will be listed for each subject and 
sampling time and summarized descriptively using the arithmetic mean, SD, CV (%), median, 
minimum and maximum. Individual plasma conc entrat ion-time profiles of insulin and C -peptide 
will be plotted on both a linear and a semi -logarithmic scale. Mean values will also be presented 
graphically.  
8.3 Continuous Glucose Monitor  Evaluation  
For the purpose of analysis:  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 53 
CONFIDENTIAL   24-hour will be considered to be from 6AM to 6AM,  
 Daytime will be considered to be from 6AM to 10PM, and  
 Nighttime will be considered to be from 10PM to 6AM.  
The last [ADDRESS_427250] 80% of expected measurements prior to dosing will be considered 
the run -in days for each of the param eters. The last [ADDRESS_427251] 80% of expected 
measurements prior to [ADDRESS_427252] dose will be considered the follow -up days.  
The area under th e curve (AUC) will be derived for each of the time periods (24 -hour, daytime 
and nighttime) using the indicated days (run -in days, treatment days and follow -up days). The 
average glucose measurement will be derived by [CONTACT_344272]. The average change from run -in will be derived for each treatment regimen for both the 
treatment days and the follow -up days.  
The placebo adjusted change in means will be derived for each of the active therapy regimens by 
[CONTACT_344273] o mean (the mean change from run -in while the subject was receiving 
placebo) from the active therapy mean (the mean change from run -in while the subject was 
receiving the active therapy).  The placebo adjusted change in means will be derived for both the 
treatment days and the follow -up days.  
The placebo adjusted change in means will be analyzed using an Analysis of Variance 
(ANOVA) with treatment as the main effect to determine whether multiple doses a day has an 
effect on the CGM parameters.  
The ratios of  the placebo adjusted change in means between the active treatments within each 
subject will also be derived to estimate the magnitude of the dose response.  
Summary statistics will be presented for both the placebo adjusted change in means and the ratios 
of the placebo adjusted change in means. Analysis results will be presented for the change in 
means.  
8.[ADDRESS_427253] current version of MedDRA .  The severity of AEs will be 
graded according to NCI CTCAE version 4.03.  AEs will be regarded as “pretreatment”  if they 
occur during the placebo washout period or placebo run -in period.  TEAEs are defined as any 
AE that starts  or increases in severity after the first randomized dose of study treatment  on Visit 
2/Day 4. 
The incide nce of TEAEs  will be tabulated by [CONTACT_6213], system organ class, 
treatment group , severity, and assigned relationship t o study treatment .  The incidence for each 
TEAE  will be provided as the total number of subjects that experienced the TEAE , as well as the 
percentage of the population that thi s represents.  If a TEAE  is reported more than once for a 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427254] -case attribution will be presented in the 
summary tables.  
TEAEs  will be listed for individual subjects, along with information regarding onset  and end 
dates, onset time where available , severity, seriousness, relationship t o study treatment , action 
taken, and outcome.  A similar listing will be prepared for the pretreatment AEs.   
Pretreatment AEs and TEAEs that lead to withdrawal from the study will  be separately listed and 
summarized.  Similarly, separate tabulation s and listing s will be prepared for pretreatment and 
treatment -emergent SAEs .  
Descriptive statistics will be generated as appropriate (i.e., frequency for categorical data).  
Inferential  statistical analysis comparing the AE data between active and placebo  is not planned.  
8.4.3  Laboratory  Evaluations  
Individual clinical safety lab (hematology, serum chemistry, and urinalysis)  values will be listed 
by [CONTACT_248460] (i.e., mean, median, range, 
and standard deviation for continuous data and frequency for categorical data) .  Individual 
change from baseline  (Screening ) in lab oratory  values will be calculated and  summarized 
descriptively.  Shift tables from baseline  (Visit 2/Day 1 ) to postdose ( Visit 3) will also be 
produced for the laboratory assessments based on the categories of Low, Normal, and High.  A 
clinically significant change from baseline  (Screening ) will be recorded as a n AE if deemed 
appropriate by [CONTACT_737] . 
8.4.4  Vital Signs  
Individ ual vital sign measurements ( height, weight, seated SBP/DBP,  heart rate , and 
temperature ) will be listed by [CONTACT_344274] (i.e., mean, median, range, and standard deviation ).  Individual change from baseline  
(predose Day 1) in vital sign measurements will be calculated and summarized descriptively.  A 
clinically significant change from baseline  (predose Day 1) will be recorded as a TEAE if 
deemed appropriate by [CONTACT_737] . 
8.4.5  12-lead ECG  
Individ ual 12 -lead ECG assessments  will be listed by [CONTACT_344275] (i.e., mean, median, range, and standard deviation for c ontinuous data 
and frequency for categorical data) .   
8.4.6  Physical Examination  
Individ ual physical examination findings  will be listed by [CONTACT_765].  A clinically significant change 
from baseline  (Screening ) will be recorded as an AE if deemed appropriate by [CONTACT_737] . 
8.4.[ADDRESS_427255], which employs the Anatomical Therapeutic Chemical classification system .   
All medications and supplements  (other than study treatment ) taken by [CONTACT_248463] 
2/Day 1  through the Visit 3 will be considered “concomitant ” medications  and supplements .  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 55 
CONFIDENTIAL  Medications and supplements taken prior to Visit 2/Day 1 that are no lon ger being taken at the 
time of Visit 2/Day 1 will be considered “prior ” medications  and supplements .   
Concomitant medications and supplements will be listed for individual subjects.  A similar 
listing will be prepared for prior medications and supplements  taken within [ADDRESS_427256] dose o f study treatment .  The incidence of these prior and concomitant medications and 
supplements will be summarized.  
8.4.8  Handling of Missing, Unused, or Spurious Data  
Descriptive statistics and listings will be provid ed for all data.  No substitution of missing data 
will be used in any calculations.  Data points that appear to be spurious will be investigated and 
will not be excluded from the listings.  Influential cases will be handled in an appropriate 
statistical manner.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427257] research organization’s  (CRO’s ) SOPs.  
9.2 Electronic Data Capture  
Data from the source documents  will be  entere d into the electronic data capture (EDC) system by 
[CONTACT_344276] .  Data Management staff, using both electronic and 
manu al checks, will systematically check  the data.   Errors or omissions will result in queries  
(which can be iss ued by [CONTACT_248465]) , which will be  presented 
to the Investigational Site within the EDC system .  The Investigational Site will resolve the 
queries within the EDC system.  The Study Monitor and Data Management staff will revie w the 
responses as part of the query resolution process.  The EDC system will track the queries with 
the corresponding responses.  
Medications and supplements entered into the database will be coded in the EDC system using 
the World Health Organization ( WHO ) Drug Reference List, which employs the Anatomical 
Therapeutic Chemical classification system.  AEs and Medical History will be coded in the EDC 
system using MedDRA terminology.  
Clinical laboratory samples will be processed by  [CONTACT_344277]/PD samples will be processed 
by [CONTACT_344278] [ADDRESS_427258]., Israel  and the  results will be sent 
electronically to Integrium. The clinical laboratory results will be imported into the database.  
9.3 Quality Assurance and Database Lock  
A 100% critical variable review of all key safety and  secondary endpoint  data in the database 
will be performed.  Following this review, a data quality control audit or a random sample equal 
to the square root plus 1 of the total population  will be performed.  
When the database has been declared to be complete and accurate, the database will be locked.   
Any changes to the database after that time can only be made by [CONTACT_248467], the Investigator, Integrium , and the study biostatistician . 
 
10 AMENDMENTS/MODIFICAT IONS OF THIS PROTOCOL  
The Investigator will ensure that the study is conducted in accordance with the procedures and 
evaluations described in this protocol.  As the study progresses it may become necessary to 
change or modify parts of the protocol.  The Sponsor or desi gnee is responsible for submitting 
protocol amendments to the appropriate government regulatory authorities.  The Investigator is 
responsible for submitting protocol amendments to the appropriate IRB.  Approval by [CONTACT_344279] e implemented.    
When an emergency occurs that requires a departure from the protocol for an individual, a 
departure will be only for that subject.  The Investigator or other physician in attendance in such 
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427259] (for whom the departure from protocol was affected) is to continue in the 
study.  The CRF and so urce documents will completely describe the departure from the protocol 
and state the reasons for such departure.  In addition, the IRB will be notified in writing of such 
departure from protocol.  
11 INVESTIGATOR OBLIGAT IONS  
11.1 Regulatory Documentation  
Before th e trial starts, E ssential Documents as defined in ICH E6 will be generated and placed in 
both the  Investigator’s and Sponsor’s files.  Additional Essential Documents will be added to 
both files as new information becomes available and at the completion or termination of the trial 
as defined in ICH E6.  
11.[ADDRESS_427260] this study in accordance with the Declaration of Helsinki (1964) 
including all amendments up to and including the October [ADDRESS_427261] this study in accordance with the principles of GCP (current ICH 
guidelines) and the requirements of all local regulatory authorities regarding the conduct of 
clinic al trials and the protection of human subjects.  
The study will be conducted as described in the approved protocol, with amendments and in 
accordance with the obligations of clinical Investigators set forth in the Form FDA [ADDRESS_427262]  
The Investigator is responsible for the submission of t he protocol , ICF, and other written 
materials (such as advertisements and diaries), along with  relevant supporting data  (e.g., IB),  to 
the appropriate IRB for review an d approval before the study can be initiated.  The Investigator 
is also responsible for submitting a mendments to the protocol  and ICF  to the IRB for review and 
approval prior to implementation of the change.  The Investigator is responsible for providing the 
Sponsor with a letter documenting the IRB approval prior to initiation of the study  or 
implementation of the changes, respectively .  
The Investigator will not have authority to implement any deviation or change  to the protocol 
without prior review and documented approval/favorable opi[INVESTIGATOR_335932], except where necessary to eliminate an immediate hazard to study subjects.  Any 
significant deviation from the approved protocol will be documente d in the source documents 
and case report form ( CRF) .  
Any deviation or change to the protocol required to eliminate an immediate hazard prior to 
obtaining IRB approval/favorable opi[INVESTIGATOR_1649], will be submitted as soon as possible to:  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 58 
CONFIDENTIAL   IRB for review and approv al/favorable opi[INVESTIGATOR_1649].  
 The Sponsor  via appropriate designees.  
 Regulatory Authorities, if required by [CONTACT_427].  
Documentation of IRB approval signed by [CONTACT_344280].  
If an Amendment substantially alters the study design or increases the potential risk to the 
subject: (1) the ICF will be revised and submitted to the IRB for review and approval/favorable 
opi[INVESTIGATOR_1649]; (2) the revised ICF will be u sed to obtain consent from subjects currently enrolled in the 
study if they are affected by [CONTACT_12716]; and (3) the new ICF will be used to obtain consent 
from any new subjects prior to enrollment.  
The Investigator is responsible for informing the IRB o f all reportable AEs.  IND Safety Reports 
provided by [CONTACT_344281].  Updates to the IB provided by [CONTACT_344282] . 
The Investigator  is also responsible for informing the IRB of the progress of the study and for 
obtaining annual IRB renewal.  The Investigator must inform the IRB when the study is 
completed or terminated.  After completion or termination of the study, the Investigator will 
submit the final clinical study report to the  IRB.  The structure and content of the report will 
meet that described in Structure and Content of Clinical Study Reports E3 (ICH Harmonized 
Tripartite Guideline, dated November 30, 1995).   
11.1.[ADDRESS_427263] comply with informed consent regulations (21  CFR Part 50) and relevant 
state regulations (i.e., [LOCATION_004] Bill of Rights for [LOCATION_004] patients).   
The ICF will clearly describe the nature, scope, and potential risks and benefits of the study , in a 
language that the subject understands.  The ICF will  conform to  all the requirements for 
informed consent according to ICH GCP and  US FDA guidelines (21 CFR 50) and will include 
any additional elements required by [CONTACT_737]’s institution or local regulatory authorities.  
The ICF will adhere  to the ethical principles that have their origin in the Declarati on of Helsinki.   
Prior to the beginning of the study, the Investigator will obtain the IRB’s  written 
approval/favorable opi[INVESTIGATOR_248426].  The IRB approved ICF will be given to each 
prospective participant.  The subjects will be given adequate time to discuss the stu dy with the 
Investigator or site staff and to decide whether or not to participate.  Each subject who agrees to 
participate in the trial and who signs the ICF will be given a copy of the signed, dated, and 
witnessed document.  The original signed ICF will be retained by [CONTACT_344283].  
The ICF  and any other information provided to subjects will be  revised whenever important new 
information bec omes available that is relevant to the subject's consent, and the Investigator will 
obtain the IRB’s  written approval/favorable opi[INVESTIGATOR_248427] . 
The Investigator, or a person designated by [CONTACT_737], will fully inform the subject of all 
pertinent aspects of the study and of any new information relevant to the  subject's willingness to 
continue participation in the study.  Subject s will  read and sign any and all revised ICFs .  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427264] to the subjects’ state of 
health will be re garded as confidential.  This is detailed in the ICF provided to the subject.  An 
agreement for the use or disclosure of any such information  (PHI)  will be obtained  from the 
subject  in writing (HIPAA authorization)  prior to performing any study -related pro cedures .  
Disclosure of s ubject medical information obtained as a result of this study to third parties other 
than those noted below is prohibited.   
Medical information resulting from a subject’s participation in this study may be given to the 
subject’s p ersonal physician or to the appropriate medical personnel responsible for the subject’s 
welfare.  Data generated as a result of this study are to be available for inspection on request by 
[CONTACT_24654], the Sponsor (or designee), and the IRB.    
The information developed in this clinical study will be used by [CONTACT_21411] t he clinical 
development of the Study treatment  and therefore may be disclosed by [CONTACT_344284] a public company to other clinical investigators, to other pharmaceutical 
companies, to the FDA , and to other government agencies.   All reports and communications 
relating to subjects in this study will identify each subject only by [CONTACT_344285].  
11.[ADDRESS_427265]’s CRF investigator signature [CONTACT_248485] . 
11.[ADDRESS_427266]’s medical record, hospi[INVESTIGATOR_1332], clinic ch arts, the 
Principal Investigator ’s study files, as well as the results of diagnostic tests.   
11.[ADDRESS_427267] be available for inspection 
by [CONTACT_16015] , the IRB , and regulatory authorities (i.e., FDA or inte rnational 
regulatory authorities) at any time and should consist of the Essential Documents as defined in 
ICH E6, which include, but are not limited to, the following elements:  
 Subject files, containing the co mpleted CRFs , supporting source documentation f rom the 
medical record , including labo ratory data , and the signed ICF;  
 Regulatory files, containing the protocol with all amendments and Sponsor and 
Investigator signature [CONTACT_1787], copi[INVESTIGATOR_155773], and all 
correspondence between  the site and the IRB and Sponsor ; and  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 60 
CONFIDENTIAL   Drug accountability files, including a complete account of the receipt and disposition of 
the Study treatment  (active and placebo) . 
The Investigator will retain all study r ecords for at least [ADDRESS_427268] approval of a 
marketing application in an ICH region (i.e., [LOCATION_002], Europe, or Japan) , and until there are 
no pending or contemplated marketing applications in an ICH region.  If no application is filed 
or if the application is not approved  for such indication, the Investigator will retain all study 
records for at least  [ADDRESS_427269] ure and content of the report will meet that described in Structure and Content of Clinical 
Study Reports E3 (ICH Harmonized Tripartite Guideline, dated November  30, 1995).  The 
Principal Investigator [INVESTIGATOR_344254].   
12 STUDY ADMINISTRATION  
12.1 Study  Monitoring  
This study will be monitored by [CONTACT_248475], to 
verify the accuracy and completeness of the CRFs, to assure that all protocol requirements, 
applicable laws and/or regulations, and Investigator’s obligations are being fulfilled, and to 
resolve any inconsistencies in the study records.  
The Investigat or will allow the Study Monitor  to periodica lly review, at mutually convenient 
times during the study and after the study has been completed, all CRFs and office, hospi[INVESTIGATOR_307], and 
laboratory records supporting the participation of each subject in the study.   
The Study M onitor will compare  the CRF data against source documentation in order to verify 
its accuracy and completeness.  The Investigator and Investigational Site  staff will collaborate 
with the Study Monitor to resolve any identified data  discrepancies in a timely manner.   
The Study Monitor wi ll record any p rotocol deviations identified , including, but not limited to, 
subjects that were enrolled even though they did not meet all eligibility criteria, subjects who 
took concomitant medications specifically prohibited by [CONTACT_760], subjects who  received the 
wrong study treatment  or incorrect dose, and subjects who failed to comply with the protocol -
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page [ADDRESS_427270] the s tudy treatment  inventory (unused and used) at the site.  T he Investigator and 
Investigational Site  staff will collaborate with the Study M onitor to resolve any identified 
discrepancies in a timely manner . 
Each issue identified during study monitoring visit s will be  documented  and reported  to both the 
Sponsor and the Investigator . 
12.[ADDRESS_427271] to visit the Investigator’s site to conduct an audit of 
the study .  Prior to initiating this audit, the Investigator will be contact[CONTACT_344286] a convenient time for this visit.  The Principal Investigator [INVESTIGATOR_344255] -related documents .  
12.[ADDRESS_427272] be documented in the source documents.   
Refer to Section 8 for further details regarding Data Management quality assurance, including 
query generation and resolution , final data review , and database lock.  
12.4 Publication Policy  
All information and d ata obtained in the course of the study are the property of the Sponsor and 
are considered confidential.  To avoid disclosures that could jeopardize proprietary rights, the 
institution and/or the Investigator agree to certain restrictions on publications ( e.g., abstracts, 
speeches, posters, manuscripts, and electronic communications), as detailed in the clinical trial 
agreement.  
The publication or presentation of any study results shall comply with all applicable privacy 
laws, including, but not limited to,  HIPAA or equivalent.  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 62 
CONFIDENTIAL  This trial will be registered in a publicly accessible database (clinicaltrials.gov) not later than [ADDRESS_427273] similar confidentiality from his/her staff  and the 
IRB.  Study documents provided by [CONTACT_248476]  (protocols, IBs, CRFs , and other 
material) will be stored appropriately to ensure their confidentiality.  The information provided 
by [CONTACT_344287] , except to the extent necessary to obtain 
informed consent from subjects who wish to participate in the study.  
  
Oramed Ltd.   Protocol No. ORA -D-012 
Phase 2a Clinical Study  Version 1 (August 23, 2016)  Page 63 
CONFIDENTIAL  13 REFERENCES  
American Diabetes Association (2009): “Standards of medical care in diabetes – 2009.” Diabetes 
Care 32(S1):S13 -S61. 
Centers for Disease Control and Prevention (2008): “National diabetes fact sheet: general 
information and national estimates on diabetes in the [LOCATION_002], 2007.” U.S. Departm ent of 
Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.  
Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, Zinman B, Jacobson A, 
Sun W, Lachin JM, Nathan DM; DCCT/EDIC Research Group (2006): “The effect of intensive 
glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes 
Control and Complications Trial/Epi[INVESTIGATOR_146714] 
(DCCT/EDIC) Study.” Diabetes 55(12):3556 -3565.  
Diabetes C ontrol and Complications Trial Research Group (1993): “The effect of intensive 
diabetes treatment on the development and progression of long -term complications in insulin -
dependent diabetes mellitus.” N Engl J Med 329(14):977 -986. 
Holm S (1979): “ A simple sequentially rej ective multiple test procedure.”  Scandinavian Journal 
of Statistics 6:65 –70. 
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B (2006): 
“Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the in itiation and 
adjustment of therapy: a consensus statement from the American Diabetes Association and the 
European A 1ssociation for the Study of Diabetes.” Diabetes Care 29(8):1963 -1972.  
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Z inman B (2009): 
“Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation 
and adjustment of therapy: a consensus statement of the American Diabetes Association and the 
European Association for the Study of Diabetes.”  Diabetes Care 32(1):193 -203. 
U.K. Prospective Diabetes Study ([LOCATION_006]PDS) Group (1998a): “Intensive blood glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of complication in 
patients with type 2 diabetes ([LOCATION_006]PDS 33).”  Lancet 352(9131):837 -853. 
U.K. Prospective Diabetes Study ([LOCATION_006]PDS) Group (1998b): “Effect of intensive blood glucose 
control with metformin on complication in overweight patients with type 2 diabetes ([LOCATION_006]PDS 34).” 
Lancet 352(9131):854 -865. 
U.S. Food and Dru g Administration  (2008): “Draft Guidance for Industry: Diabetes Mellitus: 
Developi[INVESTIGATOR_111391].” U.S. Department of 
Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and 
Research, Silver Spring, MD.  
World Health Organization (2006): “Definition and Diagnosis of Diabetes Mellitus and 
Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation.” World Health Organization, 
Geneva, Switzerland.  
 